Neurotrophin-3 gene therapies and compositions and uses thereof
The rAAV particle delivering NT-3 polypeptide addresses the lack of effective treatments for CMT1A by providing sustained expression, improving nerve function and reducing muscle weakness and atrophy.
Patent Information
- Application Number
- PCT/US2026/027687
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for Charcot-Marie-Tooth (CMT) disease, particularly CMT1A, are limited to supportive care, lacking an effective broad-spectrum approach to ameliorate physical symptoms such as muscle weakness, atrophy, and sensory loss.
A recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence with high identity to SEQ ID NO: 8 and an AAVrh74 capsid protein with high identity to SEQ ID NO: 9, designed to deliver a human NT-3 polypeptide for sustained expression, is administered to treat neuromuscular disorders like CMT1A.
The rAAV particle leads to sustained expression of NT-3 polypeptide, improving nerve conduction, reducing muscle weakness and atrophy, and enhancing nerve impulse signal, thereby alleviating the symptoms of CMT1A.
Smart Images

Figure US2026027687_19112026_PF_FP_ABST
Abstract
Description
140056-10212025-039-03; 8216.WOOONEUROTROPHIN-3 GENE THERAPIES AND COMPOSITIONS AND USES THEREOFCROSS-REFERENCE TO RELATED PATENT APPLICATION
[0001] This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63 / 804,470, filed May 12, 2025, the entire contents of which are incorporated herein by reference.FIELD OF DISCLOSURE
[0002] The present disclosure pertains to the medical field including gene therapy, for example, the treatment of diseases (e.g., neuromuscular disorders) by gene therapy.BACKGROUND
[0003] Charcot-Marie-Tooth (CMT) Disease, historically known as Hereditary Motor and Sensory Neuropathy (HMSN), is the most common inherited peripheral neuropathy with a reported prevalence of 1:2500.1 The disease is divided into subtypes based on the inheritance pattern, genetic cause, and pathogenic mechanisms focusing primarily on either denervation or demyelination. CMT1A is the most prevalent subtype and is defined by a duplication of the chromosome containing the gene for peripheral myelin protein 22 (PMP22).2 Over time, the overexpression of PMP22 in Schwann cells, the myelinating cells of the peripheral nervous system, leads to weakening of the cells and eventually causes Schwann cell death (Li, J., et al. Mol Neurobiol 2013, 47 (2), 673-698.). The reduction of myelination and eventual loss of myelinating capabilities in peripheral nerves results in slowed nerve conduction velocities and lowered nerve impulse signal, leading to muscle weakness and atrophy (Morena, J., et al. Int J Mol Sci 2019, 20 (14). DOI: 10.3390 / ijms20143419).
[0004] CMT1A patients typically present symptoms in the first two decades of life with difficulty walking or running. Distal muscle weakness and atrophy as well as sensory loss presents in a length-dependent manner, impacting the feet first and progressing proximally with legs more frequently and severely affected than arms. Hallmark features of CMT1 A include pes cavus (high arch foot deformity) with hammertoes and a “stork appearance” of the legs due to symmetrical muscle weakness and wasting. Proprioceptive loss causing balance difficulties and decreased14917-7286-3658.7140056-10212025-039-03; 8216.WOOO manual dexterity are also hallmarks of the disease (98-118. DOI: 10.1111 / j .1399-0004.1974.tb00638). Pain is a common symptom of CMT1A patients but is typically moderate, with limited impact on daily life (Ribiere, C., et al. Ann Phys Rehabil Med 2012, 55 (3), 160-173. DOI: 10.1016 / j. rehab.2012.02.005). CMT1A patients exhibit normal life expectancy, however physical disability increases as the disease progresses (Verhamme, C, et al. Brain 2009, 132 (Pt 12), 3252-3262. DOI: 10.1093 / brain / awp251.).
[0005] Treatment options for CMT, as with several similar demyelination-related conditions, are currently limited to supportive care. An effective, broad-spectrum treatment to ameliorate the physical symptoms of CMT subtypes and related disorders is desperately needed.BRIEF SUMMARY
[0006] In some aspects, provided herein is a recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence having at least 80% (e.g., 80%, 85%, 90%, 95%, 99% or 100%) identity to the nucleotide sequence set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising having at least 80% (e.g., 80%, 85%, 90%, 95%, 99% or 100%) identity to the amino acid sequence set forth in SEQ ID NO: 9.
[0007] In some aspects provided herein is a rAAV particle comprising a capsid protein and a payload nucleotide sequence, wherein the payload nucleotide sequence comprises a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1, a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2, an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3, a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5, an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6, and a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7 and wherein the capsid protein comprises an AAVrh74 capsid protein as set forth in SEQ ID NO: 9, or a variant thereof. In some aspects, the rAAV particle comprises a payload nucleotide sequence that has at least 95% sequence identity to SEQ ID NO: 8. In some aspects, the rAAV particle comprises a payload nucleotide sequence that has at least 99% sequence identity to SEQ ID NO: 8. In some aspects, the rAAV particle comprises the payload nucleotide sequence set forth in SEQ ID NO: 8. In some aspects, the rAAV particle comprises a pharmaceutically acceptable carrier.24917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0008] In some aspects, provided herein is an expression cassette comprising the nucleotide sequence set forth in SEQ ID NO: 8. In some aspects, the expression cassette comprises a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2, an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3, a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5, and an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6. In some aspects, disclosed herein is a vector comprising an expression cassette described above. In some aspects, the vector is an AAV vector. In some aspects, the vector further comprises a nucleotide sequence encoding a first inverted terminal repeat (ITR) and a second ITR. In some aspects, the first ITR is at the 5' of a payload nucleotide sequence and a second ITR is at the 3' of a payload nucleotide sequence. In some aspects, the first and the second ITR are of a same or of different serotypes. In some aspects, serotype of the ITRs is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrhlO, AAVrh74, AAV11, or AAV12 serotype. In some aspects, the first ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1. In some aspects, the second ITR comprises a nucleotide sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 7. In some aspects, the vector further comprises a nucleotide sequence encoding a selectable marker. In some aspects, provided herein is a pharmaceutical formulation comprising a previously described rAAV particle, expression cassette, vector, or any combination thereof and at least one pharmaceutically acceptable carrier.
[0009] In some aspects, provided herein is a nucleic acid comprising a nucleotide sequence that has at least 90% sequence identity to SEQ ID NO: 12 (pAAV.tMCK.NT3. KAN). In some aspects, the nucleic acid comprises a nucleotide sequence having at least 99% sequence identity to SEQ ID NO: 12. In some aspects, the nucleic acid comprises a nucleotide sequence set forth in SEQ ID NO: 12. In some aspects, provided herein is a cell that comprises a previously described nucleic acid. In some aspects, the cell is a packaging cell. In some aspects, the cell is selected from a HeLa cell, a human fetal kidney cell (HEK293 cell), a PerC6 cell, a human fetal fibroblast cell (MRC-5 cell), a human fetal fibroblast cell (WI-38 cell), a monkey kidney cell (Vero cell) and a rhesus fetal lung cell (FRhL-2 cell), or any combination thereof. In some aspects, provided herein 34917-7286-3658.7140056-10212025-039-03; 8216.WOOO is a method of manufacturing an infectious recombinant AAV (rAAV) particle, the method comprising contacting a previously described nucleic acid to a mammalian cell. In some aspects, the method further comprises purification of the infectious rAAV particle. In some aspects, the infectious rAAV particle serotype is AAVrh74. In some aspects, a purified rAAV particle is prepared by a previously described method.
[0010] In some aspects, provided herein is a method of treating a subject suffering from a neuromuscular disorder or neuropathy by administering a recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence which comprises the payload nucleotide sequence as set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising the amino acid sequence set forth in SEQ ID NO: 9. In some aspects, the neuromuscular disorder or neuropathy is Charcot-Marie Tooth (CMT) disease. In some aspects, the CMT disease is CMT1A. In some aspects, the CMT disease is CMT2A.
[0011] In some aspects, provided herein is a method of treating a human subject for a neuromuscular disorder or neuropathy comprising administration of a previously described rAAV particle, expression cassette, vector, pharmaceutical formulation, or any combination thereof. In some aspects, the administration comprises an intramuscular injection. In some aspects, the administration comprises an intravenous injection. In some aspects, the treatment is formulated to result in a sustained expression of NT-3 polypeptide. In some aspects, the administration of the rAAV particle, the expression cassette, the vector, and the pharmaceutical formulation results in a sustained expression of NT-3 polypeptide. In some aspects, the human subject is suffering from Charcot-Marie-Tooth (CMT) disease. In some aspects, the human subject is suffering from CMT1 A. In some aspects, the human subject is suffering from CMT2A.
[0012] In some aspects, provided herein is a use of a previously described rAAV particle, expression cassette, vector, pharmaceutical formulation, or any combination thereof for the manufacture of a medicament for treating a neuromuscular disorder or neuropathy in a human subject. In some aspects, the rAAV particle, the expression cassette, the vector, or the pharmaceutical formulation is to be administered via intramuscular injection. In some aspects, the rAAV particle, the expression cassette, the vector, or the pharmaceutical formulation is to be administered via intravenous injection. In some aspects, the use comprises the medicament is formulated to result in a sustained expression of NT-3 polypeptide. In some aspects, the human subject is suffering from Charcot-Marie-Tooth (CMT) disease. In some aspects, the human subject is suffering from CMT1 A. In some aspects, the human subject is suffering from CMT2A.44917-7286-3658.7140056-10212025-039-03; 8216.WOOO BRIEF DESCRIPTION OF DRAWINGS
[0013] FIG. 1 shows analysis of NT-3 protein expression in serum, which indicates sustained dose-dependent NT-3 expression up to 41 weeks post-dosing. Circles represent males and triangles represent females. Significance indicates differences compared to that same dose at 5 weeks post-dosing. *p<0.05, **p<0.01.
[0014] FIG. 2 shows hind ankle angle with toe down gait metrics at study endpoint. Statistical comparisons are shown against the saline-treated Tr-I control group. **p<0.01.
[0015] FIG. 3 shows representative images of toluidine-blue stained proximal (LSN-P) or distal (LSN-D) left sciatic nerve. Scale bar = 25pm.
[0016] FIGs. 4A-4F collectively show neuromuscular junction (NMI) morphometries of the motor endplate, including (FIG. 4A) motor endplate volume, (FIG. 4B) interior surface area, (FIG. 4C) exterior surface area, (FIG. 4D) compactness, (FIG. 4E) interior rugosity and (FIG.4F) exterior rugosity. Statistical comparisons are against the saline-treated Tr-I control group. *p<0.05.
[0017] FIG. 5 shows the serum samples obtained at endpoint from treated (NT-3) and untreated (UT) mice were assessed by ELISA and NT-3 levels were determined. Error bars are ± SEM; n = 12 for treated cohort. NT-3 serum levels were with below detection range for UT mice (n = 7).
[0018] FIGs. 6A-6D show (FIG. 6A) grip strength, (FIG. 6B) rotarod, (FIG. 6C) CMAP and (FIG. 6D) NCV results of NT-3 -treated and untreated (UT) cohort at baseline (BL) and endpoint (EP). Data are represented as mean ± SEM, two-way ANOVA, *p<0.05, **p<0.01, ****p<0.0001
[0019] FIGs. 7A-7C show representative semi-thin, toluidine blue-stained cross-sections of sciatic nerve from (FIG. 7A) untreated and (FIG. 7B) NT-3 treated Mfn2+ / - mice. (FIG. 7C) Histogram showing myelinated fiber (MF) density distribution. Data are represented as mean ± SEM; two-way ANOVA, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0020] FIG. 8 shows percent of innervation status of NMJs. Data are represented as mean ±SEM; two-way ANOVA, ***p < 0.001, ****p < 0.0001.
[0021] FIGs.9A-9C show the number of abnormal fibers in (FIG.9A) tibialis anterior and (FIG. 9B) gastrocnemius muscles. (FIG. 9C) shows 3 -Nitrotyrosine (3-NT) levels in54917-7286-3658.7140056-10212025-039-03; 8216.WOOO gastrocnemius muscles. Data are represented as mean ± SEM, t-test, one-way ANOVA, **p < 0.01, ***p < 0.001.DETAILED DESCRIPTION OF THE DISCLOSURE
[0022] In some aspects, disclosed herein are polynucleotides (e.g., expression cassettes) encoding such one or more therapeutic polypeptides; vectors comprising such polynucleotides (e.g., AAV vectors comprising such expression cassettes); methods of making those vectors; recombinant AAV (rAAV) particles comprising such vectors; pharmaceutical compositions comprising the polynucleotides, the vectors, and / or the rAAV particles disclosed herein; and methods of using the polynucleotides, the vectors, the rAAV particles, and / or the pharmaceutical compositions disclosed herein.Definitions
[0023] In order that the present disclosure can be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety.
[0024] The practice of the present technology will employ, unless otherwise indicated, conventional techniques of tissue culture, immunology, molecular biology, microbiology, cell biology, and recombinant DNA, which are within the skill of the art.
[0025] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the disclosure also contemplates that in some embodiments, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a complex comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.
[0026] Unless explicitly indicated otherwise, all specified embodiments, features, and terms intend to include both the recited embodiment, feature, or term and biological equivalents thereof.64917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0027] All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 1.0 or 0.1, as appropriate, or alternatively by a variation of + / - 15 %, or alternatively 10%, or alternatively 5%, or alternatively 2% and such ranges are included. It is to be understood, although not always explicitly stated, that all numerical designations are preceded by the term “about”. It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.
[0028] It is to be noted that, as used herein, the indefinite articles "a" or "an" should be understood to refer to "one or more" of any recited or enumerated component; for example, "a nucleic acid sequence," is understood to represent one or more nucleic acid sequences, unless stated otherwise. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein. The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives.
[0029] Furthermore, "and / or", where used herein, is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and / or" as used in a phrase such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Likewise, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0030] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of' and / or "consisting essentially of' are also provided.
[0031] As used herein, the term "about" refers to a value that is within 10% above or below the value being described.
[0032] The term "at least" prior to a value or series of values is understood to include the values adjacent to the term "at least," and all subsequent values (numbers, integers, or fractions) that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer, e.g., "at least 18 nucleotides of a 21- nucleotide nucleic acid molecule" means that 18, 19, 20, or 21 nucleotides have the indicated property. When "at least" is present before a series of numbers or a range, it is understood that "at least" can modify each of the numbers in the series or range. "At least" is also not limited to integers (e.g., "at least 5%" includes 5.0%, 5.1%, 5.18% without consideration of the number of significant figures).74917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0033] As used herein, "no more than" or "less than" is understood as the value adjacent to the phrase and logical lower values (numbers, integers, or fractions), as logical from context, to zero. When "no more than" is present before a series of values or a range, it is understood that "no more than" can modify each of the value in the series or range.
[0034] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
[0035] The term "derived from," as used herein, refers to a component that is isolated from or made using a specified molecule or organism, or information (e.g., amino acid or nucleic acid sequence) from the specified molecule or organism.
[0036] "Nucleic acid," "polynucleotide," and "oligonucleotide," are used interchangeably in the present application. These terms refer only to the primary structure of the molecule. Thus, these terms include double- and single-stranded DNA, as well as double- and single-stranded RNA e.g., messenger RNAs (mRNAs), genomic DNAs, plasmid DNAs (pDNAs), or complementary DNAs (cDNAs)). The terms "nucleic acid," "polynucleotide," and "oligonucleotide," as used herein, are defined as it is generally understood by the person skilled in the art as a molecule comprising two or more covalently linked nucleosides. Such covalently bound nucleosides can also be referred to as nucleic acid molecules or oligomers. Polynucleotides can be made recombinantly, enzymatically, or synthetically, e.g., by solid-phase chemical synthesis followed by purification. When referring to a sequence of the polynucleotide or nucleic acid, reference is made to the sequence or order of nucleobase moieties, or modifications thereof, of the covalently linked nucleotides or nucleosides.
[0037] As used herein, the term "nucleotide" refers to monomeric units of nucleic acid polymers (e.g., deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)). Naturally occurring nucleotides are composed of three subunit molecules: a nucleobase, a five-carbon sugar (ribose or deoxyribose), and phosphate group consisting of one to three phosphates. A nucleotide can also be a modified nucleotide, which is a nucleotide comprising a modified nucleobase, a modified sugar moiety, a modified backbone, or any combination thereof. As used herein, the term "nucleobases", also known as "nitrogenous bases" or "bases", refers to biological compounds that form nucleosides, which, in turn, are components of nucleotides. A "nucleoside" comprises a nucleobase and a sugar moiety. A "sugar moiety" may comprise ribose or deoxyribose, as present 84917-7286-3658.7140056-10212025-039-03; 8216.WOOO in naturally occurring nucleotides. As used herein, the term "backbone," and "backbone structure", refer to the connection between monomers of a nucleic acid. In naturally occurring oligonucleotides, the backbone comprises a 3 '-5' phosphodiester linkage connecting sugar moi eties of the oligomer.
[0038] As used herein, the term "coding sequence" or a sequence "encoding" refers to a particular molecule which is a nucleic acid that is transcribed (in the case of DNA) or translated (in the case of RNA) into protein, in vitro or in vivo, when operably linked to an appropriate regulatory sequence, such as a promoter. The boundaries of the coding sequence are determined by a start codon at the 5 ' (amino) terminus and a translation stop codon at the 3 ' (carboxy) terminus. Although a "stop codon" (e.g., TAG, TGA, or TAA) is not translated into an amino acid, it can be considered to be part of a coding region, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, introns, and the like, are not part of a coding region. A coding sequence can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic DNA sequences. A transcription termination sequence will usually be located 3' to the coding sequence.
[0039] As used herein, the term "exon" refers to coding sections of a DNA molecule, or of an RNA molecule which is transcribed from a DNA molecule that are translated into protein. Exons can be separated by intervening sections of DNA that do not code for proteins, known as "introns". Therefore, the term "intron", as used herein, refers to a segment of nucleic acid that is transcribed and is present in the "pre-mRNA" but excised by the splicing machinery and therefore not present in the mature mRNA transcript. Following transcription, new, immature strands of messenger RNA, called "pre-mRNA", may contain both introns and exons. These pre-mRNA molecules go through a modification process in the nucleus called splicing during which the noncoding introns are cut out and only the coding exons remain in the "mature mRNA1. Splicing produces a mature messenger RNA molecule that is then translated into a protein. The term "first exon" refers to a coding sequence or sequence of nucleic acid that encodes a polypeptide or polypeptide region and the term "second exon" refers to a different second coding sequence or sequence of nucleic acid that encodes a second polypeptide region. Where the two exons are separated by an intervening intron in the pre-mRNA, the splicing machinery operates to remove the intervening intron and join the two exons in the mature mRNA.94917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0040] The term "polyadenylation signal" refers to a nucleic acid sequence present in the RNA transcript that allows for the transcript, when in the presence of the enzyme polyadenyl transferase, to be polyadenylated.
[0041] The term "promoter," as used herein in, refers to a sequence sufficient to direct transcription, in a cell. A promoter is intended as a DNA region to which RNA polymerases bind and that directs the enzyme to transcribe an operably linked DNA sequence. A DNA sequence is operably linked to a promoter if the promoter is capable of directing transcription of that DNA sequence. Promoters for use in the invention include prokaryotic, eukaryotic (e.g., mammalian or yeast), and viral promoters, e.g., the CMV (mammalian cytomegalovirus) promoter, the CAG promoter (also known as CBA promoter; CMV early enhancer / chicken P actin promoter), the UbC (polyubiquitin C gene) promoter, or the CBh (an engineered CBA promoter in which the SV40 intron is replaced with a hybrid intron composed of a 5' donor splice site from the chicken P-actin 5' UTR and a 3' acceptor splice site from MVM). A promoter can be a "constitutive" promoter that is a promoter that, when operably linked to a polynucleotide encoding a gene product, results in the production of a gene product in the cell under most or all conditions of the cell. A promoter can be a "regulatable" promoter that is a promoter whose activity is affected by a cis or trans acting factor (e.g., an inducible promoter, such as an external signal or agent). The term "inducible" promoter means that when the promoter is operably linked to a polynucleotide encoding a specified gene product, it results in the production of a gene in the cell basically only when the inducer corresponding to the promoter is present in the cell. A promoter can be a "ubiquitous" promoter that is a promoter that is active in a wide range of cells, tissues and cell cycles, or a "tissue-specific" promoter, that is a promoter that has activity only or mostly in certain cell types, i.e., drives the expression of the operably linked nucleotide sequence only or mostly in certain cell types. A promoter can be a "bidirectional" promoter, which is a promoter that is an intergenic region between two divergent genes located on complementary strands of the DNA, and drives their coordinated transcription in opposite directions.
[0042] As used herein, the term "regulatory sequence" refers to a nucleic acid sequence capable of regulating the expression of a nucleic acid sequence operably linked to said regulatory sequence, non-limiting examples of regulatory sequences are enhancers (a DNA sequence that increases the level of transcription of an operably linked gene), and silencers (a DNA sequence that decreases the level of transcription of an operably linked gene). The term "regulatory sequence" also refers to nucleic acid sequence in RNA transcripts capable of regulating, for 104917-7286-3658.7140056-10212025-039-03; 8216.WOOO example, the processing or the expression of said transcripts. Non-limiting examples of regulatory sequences that can be in RNA transcripts are nucleotide sequences that regulate localization or splicing of said RNA transcripts. The term "regulatory sequence" further refers to an amino acid sequence capable of regulating, for example, the localization (e.g., subcellular localization signals, such as nuclear localization signals), or the stability (e.g., degradation signals) of a protein.
[0043] The terms "operatively linked," "operatively inserted," "operatively positioned," "under control" means, with reference to two or more nucleic acid sequences, that the nucleic acid sequences are arranged in such a way that one of the two or more nucleic acid sequences can mediate a function that is exerted upon at least one of the other two or more nucleic acid sequences. For example, a regulatory nucleic acid sequence e.g., a promoter, an enhancer, or a silencer) can be "operatively linked," to a coding nucleic acid sequence, that is the regulatory nucleic acid sequence is in the correct location and orientation in relation to the coding nucleic acid sequence to control expression of the coding nucleic acid sequence (e.g., via control of RNA polymerase initiation). Wherein a regulatory nucleic acid sequence (e.g., a promoter, an enhancer, or a silencer) is "operatively linked," to a coding region, the coding region is "under transcriptional control" of the regulatory nucleic acid sequence (e.g., a promoter, an enhancer, or a silencer).
[0044] The term "operably linked" means that a nucleic acid sequence and a regulatory sequence(s) are arranged in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s). The term "operably inserted" means that a nucleic acid sequence of interest is positioned adjacent a regulatory nucleic acid sequence which directs transcription and translation of the nucleic acid sequence of interest (i.e., facilitates the production of, e.g., a polypeptide encoded by a DNA of interest).
[0045] As used herein, the term "RNA" relates to a nucleic acid molecule that comprises ribonucleotide residues. In some aspects, the RNA contains all or a majority of ribonucleotide residues. As used herein, "ribonucleotide" refers to a nucleotide with a hydroxyl group at the 2'-position of a b-D-ribofuranosyl group. RNA encompasses without limitation, double stranded RNA, single stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as modified RNA that differs from naturally occurring RNA by the addition, deletion, substitution and / or alteration of one or more nucleotides. Such alterations may refer to addition of non-nucleotide material to internal RNA nucleotides or to the end(s) of RNA. It is also contemplated herein that nucleotides in RNA may be non-standard 114917-7286-3658.7140056-10212025-039-03; 8216.WOOO nucleotides, such as chemically synthesized nucleotides or deoxynucleotides. For the present disclosure, these altered RNAs are considered analogs of naturally-occurring RNA. The term "mRNA," as used herein, refers to a single stranded RNA that encodes the amino acid sequence of one or more peptide (e.g., oligopeptide, or polypeptide) or protein. The term "mRNA," as used herein includes in vitro transcribed RNA (IVT RNA) or synthetic RNA. An mRNA molecule may also contain a 5' untranslated region (5'-UTR), and / or a 3' untranslated region (3'-UTR). In some aspects, the RNA is produced by in vitro transcription or chemical synthesis. In some aspects, the mRNA is produced by in vitro transcription using a DNA template where DNA refers to a nucleic acid that contains deoxyribonucleotides.
[0046] As used herein the term "splicing" refers to the process by which introns are removed from primary transcripts (pre-mRNA) and exons are joined to form the mature mRNA. Introns are removed by the pre-mRNA by cleavage at conserved sequences called "splice sites", or "splicing sites". These sites are located at the 5' and 3' ends of introns. Most commonly, the RNA sequence that is removed begins with the dinucleotide GU at its 5' end, and ends with AG at its 3' end. These consensus sequences are known to be critical, because changing one of the conserved nucleotides may result in the inhibition of splicing. Another important sequence occurs at what is called the branch point, located anywhere from 18 to 40 nucleotides upstream from the 3' end of an intron. The branch point always contains an adenine, but it is otherwise loosely conserved. A typical sequence is YNYYRAY, where Y indicates a pyrimidine, N denotes any nucleotide, R denotes any purine, and A denotes adenine. Rarely, splice site sequences are found that begin with the dinucleotide AU and end with AC, these are spliced through a similar mechanism.
[0047] Splicing occurs in several steps and is catalyzed by small nuclear ribonucleoproteins (snRNPs, commonly pronounced "snurps"). First, the pre-mRNA is cleaved at the 5' end of the intron following the attachment of a snRNP called U1 to its complementary sequence within the intron. The cut end then attaches to the conserved branch point region downstream through pairing of guanine and adenine nucleotides from the 5' end and the branch point, respectively, to form a looped structure known as a lariat. The bonding of the guanine and adenine bases takes place via a chemical reaction known as transesterification, in which a hydroxyl (OH) group on a carbon atom of the adenine attacks the bond of the guanine nucleotide at the splice site. The guanine residue is thus cleaved from the RNA strand and forms a new bond with the adenine.
[0048] Next, the snRNPs U2 and U4 / U6 appear to contribute to positioning of the 5' end and the branch point in proximity. With the participation of U5, the 3' end of the intron is brought 124917-7286-3658.7140056-10212025-039-03; 8216.WOOO into proximity, cut, and joined to the 5' end. This step occurs by transesterification; in this case, an OH group at the 3' end of the exon attacks the phosphodiester bond at the 3' splice site. The adjoining exons are covalently bound, and the resulting lariat is released with U2, U5, and U6 bound to it. In addition to consensus sequences at their splice sites, eukaryotic genes with long introns also contain exonic splicing enhancers (ESEs). These sequences, which help position the splicing apparatus, are found in the exons of genes and bind proteins that help recruit splicing machinery to the correct site. Most splicing occurs between exons on a single RNA transcript, but occasionally trans-splicing occurs, in which exons on different pre-mRNAs are ligated together.
[0049] The splicing process occurs in cellular machines called spliceosomes, in which the snRNPs are found along with additional proteins. The primary variety of spliceosome is one of the most plentiful structures in the cell, and recently, a secondary type of spliceosome has been identified that processes a minor category of introns. These introns are referred to as U12-type introns because they depend upon the action of a snRNP called U12 (the common introns described above are called U2-type introns). The role of U12-type introns is not yet defined, but their persistence throughout evolution and conservation between homologous genes of widely divergent species suggests an important functional basis.
[0050] As used herein, the term "alternative splicing" refers to a deviation from the constitutive splicing in which introns are removed and exon are in the order in which they appear in a gene. In alternative splicing certain exons are skipped resulting in various forms of mature mRNA from a single pre-RNA transcript. Weaker splicing signals at alternative splice sites, shorter exon length or higher sequence conservation surrounding orthologous alternative exons influence the exons that are ultimately included in the mature mRNA. Three possible mechanisms: exon shuffling, exonization of transposable elements and constitutively spliced exons, have been proposed for the origin of alternative splicing. Alternative splicing is the mechanism that accounts for the discrepancy between the number of protein-coding genes (-25,000) in humans and the >90,000 different proteins that are actually generated.
[0051] The term "expression" as used herein refers to a process by which a gene produces a biochemical, for example, an RNA transcript or a protein. The process includes any manifestation of the functional presence of the gene within the cell including, without limitation, gene knock-in, as well as both transient expression and stable expression. It may include, without limitation, transcription of the gene into messenger RNA (mRNA), and the translation of such mRNA into protein(s). Expression of a gene produces a "gene product." As used herein, a gene product can 134917-7286-3658.7140056-10212025-039-03; 8216.WOOO be either a nucleic acid, e.g., a messenger RNA, or a non-coding RNA, produced by transcription of a gene, or a protein, which is translated from an mRNA transcript. Gene products described herein further include nucleic acids with post transcriptional modifications, e.g., mRNAs which are processed, for example, by capping, splicing, and / or polyadenylation, or peptides with post translational modifications, e.g., methylation, glycosylation, the addition of lipids, association with other protein subunits, proteolytic cleavage, and the like. Thus, term "protein expression" refers to the process by which a nucleic acid sequence undergoes transcription (for DNA) translation (for RNA) such that detectable levels of the amino acid sequence or protein are expressed.
[0052] As used herein, the terms "protein," "polypeptide," and "peptide," are used interchangeably to refer to a natural or synthetic molecule comprising two or more amino acids linked by the carboxyl group of one amino acid to the alpha amino group of another. The amino acids may be natural or synthetic, and can contain chemical modifications such as disulfide bridges, substitution of radioisotopes, phosphorylation, substrate chelation (e.g., chelation of iron or copper atoms), glycosylation, acetylation, formylation, amidation, biotinylation, and a wide range of other modifications. A polypeptide may be attached to other molecules, for instance molecules required for function. Examples of molecules which may be attached to a polypeptide include, without limitation, cofactors, polynucleotides, lipids, metal ions, phosphate, etc. A polypeptide is comprised of approximately twenty, standard naturally occurring amino acids, although natural and synthetic amino acids, which are not members of the standard twenty amino acids, may also be used. The standard twenty amino acids include alanine (Ala, A), arginine (Arg, R), asparagine (Asn, N), aspartic acid (Asp, D), cysteine (Cys, C), glutamine (Gin, Q), glutamic acid (Glu, E), glycine (Gly, G), histidine, (His, H), isoleucine (He, I), leucine (Leu, L), lysine (Lys, K), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), serine (Ser, S), threonine (Thr, T), tryptophan (Trp, W), tyrosine (Tyr, Y), and valine (Vai, V). These letters as used in terms of a " polypeptide sequence" or "amino acid sequence" are an alphabetical representation of a polypeptide molecule. A polypeptide may be naturally occurring, recombinant, or synthetic, or any combination of these. A polypeptide may also comprise a fragment of a naturally occurring polypeptide. The term polypeptide may also apply to amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid.
[0053] A polypeptide as disclosed herein can be of a size of about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more,144917-7286-3658.7140056-10212025-039-03; 8216.WOOO 1,000 or more, or 2,000 or more amino acids. Polypeptides can have a defined three-dimensional structure, although they do not necessarily have such structure. Polypeptides with a defined three-dimensional structure are referred to as folded, and polypeptides that do not possess a defined three-dimensional structure, but rather can adopt a large number of different conformations, and are referred to as unfolded. Non-limiting examples of polypeptide include polypeptide fragments, denatured / unstructured polypeptide, polypeptide having a primary, a polypeptide, a polypeptide, or a polypeptide or aggregated structure, etc. A polypeptide may be a single molecule or may be a multi-molecular complex. There is expressly no requirement that a polypeptide must contain an intended function; a polypeptide can be functional, non-functional, function for unexpected / unintended purposes, or have unknown function.
[0054] As used herein, the term "domain" when referred to a polypeptide means a distinct functional and / or structural portion of a polypeptide. Usually domains are responsible for a particular function or interaction, contributing to the overall role of a polypeptide. Domains may exist in a variety of biological contexts, where similar domains can be found in polypeptide with different functions. For example, an "actin-binding domain" or "ABD" is to be understood as a portion of a polypeptide that is involved in the binding of the polypeptide with actin. For example, an ABD can comprise one or more amino acids that directly bind to actin.
[0055] As used herein, the term "truncated" when referred to a protein means a protein that is lacking one or more portion with the respect to the full length protein. A protein can lack, for example, an amino-terminal portion, a carboxy-terminal portion, any portion in between the two termini, or any combination thereof.
[0056] By "isolated" molecule (e.g, a protein or a nucleic acid molecule) is intended a molecule, which has been removed from its native environment. An isolated molecule includes molecules produced and maintained (e.g, upon purification) in vitro, or recombinant molecules maintained in host cells or purified (partially or substantially) from the host cell and maintained in solution. Non-limiting examples of isolated molecules include proteins or nucleic acid molecules extracted from a cell, produced synthetically (i.e., by chemical synthesis), produced by enzymatic digestion; DNA molecules produced by PCR, produced by in vitro retro-transcription (cDNA), by molecular cloning in a vector (e.g., a viral or a non-viral vector); RNA transcripts produced by in vitro transcription or produced in host cells (e.g., a heterologous host cells) and maintained in the host cell or purified (partially or substantially) from the host cell and maintained outside of the cell; proteins produced by in vitro translation or produced in host cells (e.g., a heterologous host 154917-7286-3658.7140056-10212025-039-03; 8216.WOOO cells) and maintained in the host cell or purified (partially or substantially) from the host cell and maintained outside of the cell.
[0057] As used herein, "purify," "purified," "purification" means to make substantially pure or clear from unwanted components, material defilement, admixture or imperfection.
[0058] As used herein, the term "variant" refers to an alternative molecule (e.g., an alternative genomic sequence, transcript, or protein) that differs from the corresponding wild type molecule. As used herein, the term "wild type," refers to a strain, a molecule (e.g., a nucleic acid (e.g., a gene or a transcript) or a protein) or characteristic, which prevails among individuals in natural conditions, and it is distinct from a variant of the strain, molecule (e.g., nucleic acid (e.g., gene or transcript) or protein), or characteristic. A variant may differ from the wild type molecule in any region of the molecule, for example, in any domain of a protein, in any regulatory region of a protein or nucleic acid molecule, or in any coding or non-coding region of a nucleic acid molecule, or any combination thereof. A variant may be present in any percentage of the population (e.g., <0,001%, or >10%). A variant may or may not cause phenotypic changes, and may or may not cause a disorder, disease, syndrome, or condition. A variant can be present in all the cells of an individual, or in some of the cells of the individual (e.g., in some cell lineages of the individual).
[0059] A variant genomic sequence or transcript can comprise one or more nucleotide differences with respect to the wild type sequence, such as indels (i.e., insertions and / or deletion), nucleotide expansions, transversions, translocations, inversions, chromosomal structure alterations, gene fusions, chromosome fusions, truncations, amplifications, duplications, chromosomal lesions, or any combination thereof. As a result, a variant nucleotide sequence can be altered at a single nucleotide, which may be added, deleted, or substituted, or at more than one nucleotide. Further the structure of a chromosome can be altered, with regions being flipped, deleted, duplicated, truncated, or translocated. The expression of a gene can also be amplified (or reduced) through increased (or decreased) copy number of a gene; this scenario is defined as "copy number variation. "
[0060] A variant genomic sequence can arise, for example, from unrepaired DNA damage, replication errors, or mobile genetic elements. A variant genomic sequence can be inherited from parents (i.e., may be present in the germline of one or both parents) or can be acquired over the life of an individual (i.e., appear at any time over the life of an individual in the somatic or germ line of the individual). It is also to be understood that "a copy of a gene that is not a wild type copy of the gene," is herein intended to refer to a variant of the gene. It is understood, that a gene (e.g., the 164917-7286-3658.7140056-10212025-039-03; 8216.WOOO DMD gene) is to be intended as the whole genomic region, i.e., comprising coding regions, noncoding regions, regulatory regions, or any combination thereof.
[0061] It is to be understood that the term a "variant" further encompasses proteins encoded by variant genomic sequences or transcripts.
[0062] A variant transcript can also be encoded and / or produced from the same genomic region from which the wild type molecule is encoded and / or produced, but yet differ from the wild type molecule encoded and / or produced from the same genomic region as a results of differences introduced during the transcription process and / or during RNA processing (e.g., may be the product of alternative splicing).
[0063] Additionally, a variant protein can be encoded or produced from the same genomic region or transcript as the wild type protein, but yet differ from the wild type protein as a results of differences introduced during the translation process.
[0064] As used herein, the term "recombinant DNA / RNA technology" refers to the manipulation of nucleic acid sequences outside of an organism. This technology comprises, but is not limited to, combining nucleic acid sequences (e.g. , coding sequences, regulatory elements (e.g. , promoters, enhancers, silencers, termination sequences), linkers (e.g., spacers, internal ribosome entry sites, cleavage sites)) derived from a variety of sources, inserting nucleic acid sequences from a variety of sources in appropriate vectors e.g., delivery vectors, expression vectors, integrating vectors), modifying or altering nucleotide sequences (e.g., by mutagenesis, insertion of modified nucleotides, 5'-capping, polyadenylation), synthesizing artificial nucleotide sequence. A variety of techniques described in the literature (e.g., molecular cloning, polymerase chain reaction (PCR), digestion with restriction enzymes, in vitro ligation, mutagenesis, site-directed mutagenesis, prokaryotic and eukaryotic cell transformation or transduction, in vitro DNA / RNA synthesis, in vitro RNA-5'-capping, in vitro RNA-polyadenylation, complementary DNA (cDNA) synthesis, nucleic acid isolation, and the like) can be used to manipulate nucleic acid sequences outside an organism (see for example Green & Sambrook Molecular Cloning: A Laboratory Manual, volumes 1-3, 4thedition).
[0065] As used herein, the term "recombinant" or "engineered" refers to any nucleic acid (e.g., DNA, or RNA), peptide (e.g., oligopeptide, polypeptide, protein, or protein domain), cell, or organism, which is made by manipulation of nucleic acid or amino acid sequences. For example, "engineered DNA" molecules are DNA molecules that are manipulated outside of (e.g., via recombinant DNA / RNA technology) or inside an organism (e.g., via transgenesis), to obtain a non- 174917-7286-3658.7140056-10212025-039-03; 8216.WOOO naturally occurring DNA molecule. An "engineered DNA" molecule can comprise, for example, one or more nucleotide variations compared to the DNA molecule from which it is derived. The "engineered DNA" molecule can be transcribed into RNA, which is referred to as an "engineered RNA" molecule. The "engineered RNA" molecule can be translated into a polypeptide or a polypeptide domain, which is referred to as an "engineered polypeptide" or an "engineered polypeptide domain." Thus, an "engineered polypeptide" or an "engineered polypeptide domain" can be any polypeptide or polypeptide domain, which is encoded by nucleic acids manipulated via recombinant DNA / RNA technology, additionally, an "engineered polypeptide" or an "engineered polypeptide domain" can be produced by chemical synthesis. An "engineered polypeptide" or an "engineered polypeptide domain" can be for example a truncated polypeptide or polypeptide domain, or a polypeptide or polypeptide domain comprising one or more amino acid substitutions compared to a same polypeptide or polypeptide domain that is not engineered.
[0066] An engineered polypeptide or polypeptide domain can be manipulated without the purpose of achieving a desired altered function of the polypeptide or polypeptide domain, or with the purpose of achieving a desired altered function of the polypeptide or polypeptide domain. For example, an engineered polypeptide or polypeptide domain can be modified to increase a function or characteristic of the polypeptide or polypeptide domain (e.g., to increase the binding affinity of the engineered polypeptide or polypeptide domain for a specific target (e.g., a second polypeptide or polypeptide domain)). These modifications are referred to as gain-of-function / characteristic modifications and result in gain-of-function / characteristic polypeptides or polypeptide domains. For example, a polypeptide or polypeptide domain can be modified to achieve increased binding affinity to a specific target (e.g., a second polypeptide or polypeptide domain) (z.e., the function / characteristic of the polypeptide or polypeptide domain that is increased by the modification is the binding affinity to a specific target of the polypeptide or polypeptide domain), these modified polypeptides or polypeptide domains are referred to as gain-of-affinity or GoA-polypeptides or GoA-polypeptide domains. Alternatively, a polypeptide or polypeptide domain can be modified to decrease a function or characteristic of the polypeptide or polypeptide domain. These modification are referred to as loss-of-function / characteristic modification, resulting in loss-of-function / characteristic polypeptide or polypeptide domains).
[0067] As used herein the term "amino acid substitution" refers to the replacement of one amino acid in a protein with a different amino acid. An "amino acid substitution" can be naturally occurring or experimentally induced. For example, an "amino acid substitution" can be introduced 184917-7286-3658.7140056-10212025-039-03; 8216.WOOO in a protein via manipulation of the nucleic acid molecule encoding for the protein by "recombinant DNA / RNA technology." Typically, amino acid substitution are indicated as XNY, wherein X indicates the amino acid present at position N before the amino acid substitution, and Y in indicates the amino acid present at position N after the amino acid substitution. Thus, for example T20A indicates that a T was present at position 20 before the amino acid substitution, and an A is present at the same position 20 after the amino acid substitution.
[0068] As used herein, the term "genetic locus, " refers to the physical site or location within a genome of a specific DNA sequence, for example a gene.
[0069] As used herein, the term "transgene" refers to a gene (e.g., micro-dystrophin gene) or a nucleic acid molecule that is introduced into a cell. An example of a transgene is a nucleic acid encoding a therapeutic protein. In some aspects, the gene can be present, but in some cases, the gene is not expressed or is expressed at an insufficient level in the cell. In this context, "insufficient" means that although said gene is expressed in the cell, a condition and / or disease could still be developed. In certain aspects, the transgene allows for the increased expression or over-expression of the gene. The transgene can comprise sequences that are native to the cell, sequences that do not naturally occur in the cell, or combinations of both. In certain aspects, the transgene can comprise a sequence that can be operably linked to appropriate regulatory sequences for expression of the gene in the cell. In some aspects, the transgene is integrated into the host cell's genome. In some aspects, the transgene is not integrated into the host cell's genome.
[0070] The term "vector" as used herein includes any vectors known to the skilled person including plasmid vectors, cosmid vectors, phage vectors such as lambda phage, viral vectors such as retroviral, adenoviral or baculoviral vectors, or artificial chromosome vectors such as bacterial artificial chromosomes (BAC), yeast artificial chromosomes (YAC), or Pl artificial chromosomes (PAC). Said vectors include expression as well as cloning vectors. Expression vectors comprise plasmids as well as viral vectors and generally contain a desired coding sequence and appropriate DNA sequences necessary for the expression of the operably linked coding sequence in a particular host organism (e.g., bacteria, yeast, plant, insect, or mammal) or in in vitro expression systems. Cloning vectors are generally used to engineer and amplify a certain desired DNA fragment and may comprise specific functional sequences needed for insertion and / or expression of the desired DNA fragments. A "vector" can be any vehicle for the cloning of and / or transfer of a nucleic acid into a host cell, such as a plasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc. The term "vector" includes both viral and nonviral vehicles for introducing the 194917-7286-3658.7140056-10212025-039-03; 8216.WOOO nucleic acid into a cell in vitro, ex vivo or in vivo. In some aspects, insertion of a polynucleotide into a suitable vector can be accomplished by ligating the appropriate polynucleotide fragments into a chosen vector that may or not have complementary cohesive termini. Vectors can be engineered to encode selectable markers or reporters that provide for the selection or identification of cells that have incorporated the vector. Expression of selectable markers or reporters allows identification and / or selection of host cells that incorporate and express other coding regions contained on the vector. Examples of selectable marker genes described in the literature include: genes providing resistance to neomycin, ampicillin, streptomycin, gentamycin, kanamycin, hygromycin, bialaphos herbicide, sulfonamide, and the like; and genes that are used as phenotypic markers, i.e., anthocyanin regulatory genes, isopentanyl transferase gene, and the like. Examples of reporters described in the literature include: luciferase (Luc), green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), P-galactosidase (LacZ), P-glucuronidase (Gus), and the like. Selectable markers can also be considered to be reporters.
[0071] As used herein, the term "adeno-associated vector" or "AAV vector" refers to a vector comprising one or more polynucleotides of interest (e.g., transgenes, such as microdystrophin) that are flanked by AAV terminal repeat sequences (ITRs). AAV is a single-stranded DNA parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus. General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York); Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed.; and Rose, Comprehensive Virology 3:1-61 (1974)). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been transfected with a vector encoding and expressing rep and cap gene products. "AAV Cap" means AAV Cap proteins, VP1, VP2, and VP3 and analogs thereof. "AAV Rep" means AAV Rep proteins and analogs thereof. "Serotype," with respect to a vector or virus capsid, is defined by a distinct immunological profile based on the capsid protein sequences and capsid structure. Non-limiting examples of AAV serotypes are AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV6.2, AAV6P1, AAV7, AAV8, AAV8P1, AAV9, AAVrhlO, AAVrhlOPl, AAVrh74, AAVS10P4, AAVpol, AAV11, AAV12, AAV-DJ, AAV-DJ / 8, AAV-PHP.Eb, AAV-PHP.S, AAV-PHP.B, AAV2-retro, AAV2-QuadYF, AAV2.7m8, AAVS1, AAVS10, AAVrh74, AAVS1, AAVS10, AAVH15, AAVMYO (AAV9P1), AAVMYO 2 (AAVS1P1), AAVMY03 (AAVS10P1), AAV9-204917-7286-3658.7140056-10212025-039-03; 8216.WOOO RGD (e.g., MyoAAVlA, MyoAAV 1C, MyoAAV IE, MyoAAV 2A, MyoAAV 2E, MyoAAV 3 A, MyoAAV 4A, MyoAAV 4C, MyoAAV 4E, and variants thereof.
[0072] As used herein, "flanked," with respect to a sequence that is flanked by other elements, indicates the presence of one or more the elements upstream and / or downstream, z.e., 5' and / or 3', relative to the sequence. The term "flanked" is not intended to indicate that the sequences are necessarily contiguous. For example, there may be intervening sequences between the nucleic acid encoding the transgene and a flanking element. A sequence (e.g., a transgene) that is "flanked" by two other elements (e.g., ITRs), indicates that one element is located 5' to the sequence and the other is located 3' to the sequence; however, there may be intervening sequences between.
[0073] As used herein, the terms "AAV virion," "AAV viral particle," or "AAV particle" refer to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. The particle can comprises a heterologous polynucleotide (z.e., a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell). An AAV particle comprising a heterologous polynucleotide can be also referred to as a "recombinant AAV particle," "recombinant AAV vector," "rAAV particle," or "rAAV vector."
[0074] As used herein, the term "transfection" of a cell refers to the introduction of genetic material into a cell by means of a non-viral vector for the purpose of genetically modifying the cell.
[0075] As used herein, the term "transduction" of a cell refers to the introduction of genetic material into a cell by means of a viral vector for the purpose of genetically modifying the cell. For example, the coding region of a gene or of a portion thereof (e.g., a micro-dystrophin) can be administrated / delivered to a recipient cell either in vivo or in vitro, via an AAV particle resulting in the expression of the gene or portion thereof (e.g., a micro-dystrophin) in the recipient cell.
[0076] As used herein, the term "cell" or "cells" refers not only to the particular subject cell, but also to the progeny or to the potential progeny of such cell(s). The scope of the term as used herein also encompasses the progeny that may or may not in fact be identical to the parent cell because certain modifications may occur in succeeding generations due to either mutation or environmental influences. A cell can be, for example, a "muscle cell," which is a cell derived from a muscle of any kind (for example, skeletal muscle and smooth muscle, e.g. from the digestive tract, urinary bladder, blood vessels or cardiac tissue), as well as a cell differentiated in vitro to possess the characteristics of a cell derived from a muscle of any kind. Such muscle cells may be 214917-7286-3658.7140056-10212025-039-03; 8216.WOOO differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes, and cardiomyoblasts. A cell group of muscle cells can for a "muscle tissue."
[0077] The term "muscle specific control element" refers to a nucleotide sequence that regulates expression of a coding sequence that is specific for expression in muscle tissue. These control elements include enhancers and promoters. Exemplary muscle specific control elements include, but are not limited to, the MCKH7 promoter, the MCK promoter and the MCK enhancer.
[0078] As used herein, the terms “neurotrophin-3,” “NTF3,” and “NT-3” each refer to the protein product of the NTF3 gene (NCBI Gene ID: 4908; NCBI Protein Accession No.: NP_001096124.1; UniProt: P20783. Neurotrophin-3 belong to the NGF-beta family ofneutrophic factors and is expressed in the brain and peripheral tissues. NT-3 has been shown to promote survival of peripheral neurons through preservation of Schwann cells and myelination.
[0079] As used herein, the terms "pharmaceutical formulation" or "pharmaceutical composition" refer to an admixture comprising an effective amount of a therapeutically and / or prophylactic effective agent and at least one pharmaceutically acceptable excipient (e.g., carrier, diluent, stabilizer, or any combination thereof) or adjuvant. Examples of pharmaceutically acceptable excipients are, but are not limited to, carriers, binders, diluents, lubricants, thickeners, surface active agents, preservatives, stabilizers, emulsifiers, buffers, flavoring agents, colorants, amino acids, stabilizers, bulking agents, surfactants, antimicrobials, preservatives, metal ions, chelators, cyclodextrin-based excipients, polyanions, polycations, salts, solubilizers, detergents, compatible solid or liquid fillers, encapsulating substances, or any combination thereof, which are suitable for administration to a subject. Specific examples of excipient include, without limitation, sterile water, Ringer, Ringer lactate, sterile sodium chloride solution, isotonic saline, polyalkylene glycols, hydrogenated naphthalenes and, biocompatible lactide polymers, lactide / glycolide copolymers or polyoxyethylene / polyoxy-propylene copolymers, or any combination thereof. Examples of pharmaceutically acceptable carriers are, but are not limited to, lipids, polymers, polysaccharides, peptides, proteins, lipidoids, and any combination thereof. In some aspects, the lipid is selected from the group consisting of: cationic lipids, non-cationic lipids, steroid lipids, ionizable lipids, PEG-conjugated lipids, and any combination thereof. In some aspects, the fusion proteins, the expression cassettes, and the vectors disclosed herein are complexed, or packaged in a liposome, a nanoliposome, a lipid nanoparticle, a lipoplex, a micelle, a nanomicelle, a nanoemulsion, an oil-in-water emulsions, a PEG-conjugated lipid nanoparticle, a polymeric nanoparticle, a lipid-polymer hybrid nanoparticle, a polysaccharidic nanocarrier, an RNA / DNA- 224917-7286-3658.7140056-10212025-039-03; 8216.WOOO peptide nanoparticle, an RNA / DNA -peptide nanocomplex, a biomimetic nanovesicle, a lipidoid-RNA / DNA complex, a virus-like particle, dendrimer nanoparticle, a nanogel, a metallic nanoparticle, a gold nanoparticle (AuPNs), a magnetic nanoparticle, a theranostic nanoparticle, or any combination thereof. In some aspects, the combination of the fusion proteins, the expression cassettes, and the vectors disclosed herein with one or more of the carriers described herein facilitates, enhances or enables administration of the fusion proteins, the expression cassettes, and the vectors disclosed herein to the subject. In some aspects, the combination of a therapeutic agent with one or more of the carriers described herein facilitates, enhances or enables the delivery of the therapeutic agent to a target cell.
[0080] Pharmaceutically acceptable excipients for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R Gennaro edit. 1985). Pharmaceutical excipients can be selected with regard to the intended route of administration and standard pharmaceutical practice.
[0081] As used herein, a "therapeutic agent" refers to a chemical compound, a peptide, a protein, a lipid, a carbohydrate, a nucleic acid, or any other molecule or compound capable of treating, ameliorating, or reducing the symptoms of a disease, a disorder, a condition, or a syndrome, or otherwise having a beneficial effect, upon administration to a subject suffering from the disease, disorder, condition, or syndrome.
[0082] As used herein, the term "administration" refers to the administration of a composition or substance to a subject or system. Administration to an animal subject (e.g., to a mammal) can be by any appropriate route. "Administering" refers to the physical introduction of a composition or substance, which may comprising a therapeutic agent, to a subject, using any of the various methods and delivery systems known to those skilled in the art. Examples of routes of administration include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation. Administration can also be via a non-parenteral route, for example, orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example,234917-7286-3658.7140056-10212025-039-03; 8216.WOOO intranasally, vaginally, rectally, aborally, sublingually or topically. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.
[0083] As used herein, the terms "treat," "treated," and "treating" mean both therapeutic and prophylactic treatment or preventative measures wherein the object is to reverse, alleviate, ameliorate, lessen, inhibit, slow down progression, development, severity or recurrence of an undesired symptom, complication, condition, biochemical indicia of a disorder, or disease, or obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of a condition, disorder, or disease; stabilized (i.e., not worsening) state of condition, disorder, or disease; delay in onset or slowing of condition, disorder, or disease progression; amelioration of the condition, disorder, or disease state or remission (whether partial or total), whether detectable or undetectable; an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. In some aspects, treatment includes eliciting a clinically significant response without excessive levels of side effects. In some aspects, treatment includes prolonging survival as compared to expected survival if not receiving treatment. As used herein, the term "amelioration" or "ameliorating" refers to a lessening of severity of at least one indicator of a condition or disease. As used herein, the term "preventing" or "prevention" refers to delaying or forestalling the onset, development or progression of a condition or disease for a period of time, including weeks, months, or years. As used herein, the term "prophylactic" (e.g., "prophylactic agent", "prophylactic treatment", "prophylactically effective amount"), refers to any complete or partial prevention of a disease or symptom thereof and / or can be therapeutic in terms of a partial or complete cure for a disease and / or adverse effect and / or symptom attributable to the disease.
[0084] As used herein, the term "gene therapy" refers to the administration into an individual's cells and / or tissues of an exogenous molecule (e.g., a nucleic acid sequence (e.g., a polynucleotide comprising a promoter operably linked to a nucleic acid encoding a gene product capable of interfering with the genomic sequence of the individual's cells and / or tissues)) to treat, reduce the symptoms of, or reduce the likelihood of a disease, disorder, syndrome, or condition. An exogenous molecule or sequence is understood to be molecule or sequence not normally occurring in the cell, tissue and / or individual to be treated. Both acquired and congenital diseases are amenable to gene therapy.244917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0085] As used herein, the term "subject" refers to any organism to which a composition or a substance (e.g., a nucleotide molecule) can be administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include any animal. A subject can seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be under care by a trained professional for a particular disease or condition.
[0086] As used herein, the term "expression cassette" refers to a nucleic acid molecule, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleotide sequence in a competent host cell, such that a particular gene product (e.g., RNA or protein) is expressed. Expression of any gene product may be dependent upon presence of cellular factors or additional gene products from other expression cassettes. An expression cassette may be part of a vector, such as a plasmid, a viral genome, or a nucleic acid fragment. Typically, an expression cassette includes a polynucleotide to be transcribed, operably linked to a promoter.
[0087] As used herein, the terms "genetic construct" or "construct" refer to a nucleic acid molecule (RNA, DNA, or a combination thereof) made recombinantly or synthetically comprising one or more nucleotide sequences, such as a nucleotide sequence encoding (i.e., a coding sequence) a particular gene product (e.g., RNA or protein), and comprising initiation and termination signals; a regulatory element, such as a promoter; and / or a polyadenylation signal. The one or more nucleotide sequences comprised in a genetic construct can be operably linked, such that they are capable of directing expression of the coding sequence in a cell, such as a cell maintained in culture (in vitro), or a cell comprised in an individual in vivo), to which the genetic construct is administered. A genetic construct can be, for example, an expression cassette, or a vector, e.g., a vector comprising an expression cassette.
[0088] As used herein, the terms “percent identity” and / or “percent identical,” as applicable to a particular nucleotide or amino acid sequence, refer to the proportion of identical residues between this particular reference sequence and another sequence, as calculated by a pairwise alignment using the Needleman-Wunsch algorithm using a generally available alignment program, e.g., the Needle (EMBOSS) program.
[0089] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 5th ed., 2013,254917-7286-3658.7140056-10212025-039-03; 8216.WOOO Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, 2006, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure.
[0090] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
[0091] Various aspects of the invention are described in further detail in the following subsections.Payload Polynucleotides encoding NT-3 Proteins
[0092] In some aspects, disclosed herein are payload polynucleotides comprising, or alternatively consisting essentially of, or yet further consisting of a nucleotide sequence encoding a neurotrophin-3 (NT-3) polypeptide. In some aspects, the polynucleotides consist of about 0.5 kb, 1 kb, 1.5 kb, 2 kb, 2.5 kb, 3 kb, 3.5 kb, 4 kb, 4.5 kb, 5 kb, 5.5 kb, 6 kb. In some aspects, the payload polynucleotides have a size that is suitable for cloning in a vector. In some aspects, the payload polynucleotides have a size that is suitable for cloning in a viral vector. In some aspects, the payload polynucleotides have a size that is suitable for cloning in an AAV vector.
[0093] In some aspects, the payload polynucleotides disclosed herein further comprise additional nucleotide sequences. In some aspects, the payload polynucleotides disclosed herein can be expression cassettes encoding a neurotrophin-3 (NT-3) polypeptide.
[0094] In some aspects, the payload polynucleotides disclosed herein further comprise a promoter, a Kozak sequence, an enhancer, a silencer, a poly A tail, a polyadenylation signal, a 3'-UTR, a 5'-UTR, an intronic sequence, a nucleotide sequence encoding a molecular tag, a nucleotide sequence encoding a selectable marker, a nucleotide sequence encoding a self-cleaving peptide, a linker, a filler sequence, any combination thereof, or any other nucleotide sequence that may facilitate the expression of the nucleotide sequences encoding the polypeptides disclosed herein. Any further nucleotide sequences present in the polynucleotide are in the appropriate position required to exert its function. For example, the nucleotide sequence of a promoter is operably linked to the nucleotide sequence encoding the polypeptides disclosed herein.
[0095] In some aspects, the payload polynucleotide of the disclosure comprises:264917-7286-3658.7140056-10212025-039-03; 8216.WOOO (i) a MCK promoter; (ii) an intron; (iii) a nucleotide sequence encoding a human NT-3 polypeptide; (iv) an SV40 polyadenylation signal. In further aspects, the payload polynucleotide of the disclosure comprises a first ITR at the 5’ of the polynucleotide and a second ITR at the 3’ of the polynucleotide.Promoters
[0096] The promoter for the payload polynucleotides can be a constitutive, a regulatable, an inducible, an ubiquitous, or a tissue-specific promoter.
[0097] In some aspects, the promoter is a constitutive promoter. Non-limiting example of constitutive promoters are a CBA promoter, a CMV promoter, an EFla promoter, or a CAG promoter.
[0098] In some aspects, the promoter is a tissue-specific promoter. In some aspects, the promoter drives expression of the therapeutic protein, e.g., a neurotrophin-3 protein, in the brain, peripheral nervous system, muscle, kidney, lung, testis, or any combination thereof. In some aspects, the tissue-specific promoter is a muscle tissue-specific promoter. Non-limiting example of tissue-specific promoters are a MHC promoter, a a-MHC promoter, a MLC-2 promoter, a cTnC promoter, a MHCK7 promoter, MHCK promoter, a Enh358MCK promoter, a CK promoter (e.g., hCK or hCK Plus, a CK8e promoter, a MCK promoter, a dMCK promoter, a tMCK promoter (SEQ ID NO: 2), a DES promoter, a HSA promoter, a SPc5-12 promoter, a SP-301 promoter, a MHC promoter, a Sk-CRM promoter, a Sk-CRM4 promoter, or C5-12 promoter. In some aspects, the tissue-specific promoter comprises, or alternatively consists essentially of, or yet further consists of a tMCK promoter. In some aspects, the tissue-specific promoter comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 2. In some aspects, the promoter comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 2.Enhancer
[0099] In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a human skeletal actin gene element, a cardiac actin gene element, a myocyte-specific enhancer binding factor MEF (e.g., MEF2), a MyoD enhancer element, a cardiac enhancer factor (CEF) site, murine creatine kinase enhancer element, skeletal fast-twitch troponin 274917-7286-3658.7140056-10212025-039-03; 8216.WOOO C gene element, slow-twitch cardiac troponin C gene element, the slow-twitch troponin I gene element, hypozia-inducible nuclear factors, steroid-inducible element, glucocorticoid response element (GRE) or any combination thereof. In some aspects, the enhancer is a MEF2 enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of aMyoD enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a MCK enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a CEF site. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a SV40 enhancer. In some aspects, the enhancer comprises, or alternatively consists essentially of, or yet further consists of a c-Myc enhancer.Intron
[0100] In some aspects, the intron comprises, or alternatively consists essentially of, or yet further consists of a CAG intron, an SV40 intron, MVM intron, or a human beta-globin intron, or any combination thereof. In some aspects, the intron comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 3. In some aspects, the intron for the payload polynucleotide comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 3.Poly A
[0101] In some aspects, the poly (A) sequence comprises, or alternatively consists essentially of, or yet further consists of an actin poly(A), a bGHpA, a hGHpA, a SV40pA, or a synthetic pA. In some aspects, the poly(A) sequence comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 6. In some aspects, the poly(A) tail comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 6.284917-7286-3658.7140056-10212025-039-03; 8216.WOOO Inverted Terminal Repeats (ITRs)
[0102] In some aspects, the payload polynucleotides further comprise a nucleotide sequence encoding a first inverted terminal repeat (ITR) and a second ITR. In some aspects, the first inverted terminal repeat (ITR) and the second ITR are derived from the same serotype. In some aspects, the first inverted terminal repeat (ITR) and the second ITR are derived from different serotypes. In some aspects, the serotype is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrhlO, AAVrh74, AAV11, or AAV12 serotype. In some aspects, the serotype is AAV2 serotype.
[0103] In some aspects, the first ITR sequence comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 1. In some aspects, the first ITR sequence comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 1.
[0104] In some aspects, the second ITR sequence comprises, or alternatively consists essentially of, or yet further consists of a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 7. In some aspects, the second ITR sequence comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 7.Exemplary Payload Polynucleotides
[0105] In some aspects, the polynucleotides disclosed herein are isolated polynucleotides. In some aspects, the payload polynucleotide comprises:(i) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(ii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iii) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5; and(iv) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6.
[0106] In some aspects, the payload polynucleotide comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;294917-7286-3658.7140056-10212025-039-03; 8216.WOOO (iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7.
[0107] In some aspects, the payload polynucleotide comprises, or alternatively consists essentially of, or yet further consists of the nucleotide sequence set forth in SEQ ID NO: 8.
[0108] In some aspects, the polynucleotides disclosed herein are comprised in an expression cassette. In some aspects, the expression cassette is in a vector. Therefore, in some aspects, provided herein is an expression cassette comprising a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7.
[0109] In some aspects, the expression cassette comprises, or alternatively consists essentially of, or yet further consists of a payload polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 8.
[0110] In some aspects, provided herein is a vector comprising a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7.304917-7286-3658.7140056-10212025-039-03; 8216.WOOO [OHl] In some aspects, the vector comprises, or alternatively consists essentially of, or yet further consists of a payload polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 8.
[0112] Vectors comprising the polynucleotides (e.g., expression cassettes) disclosed herein are also provided for herein. In some aspects, the vectors are non-viral vectors. In some aspects, the vectors are viral vectors ( / .< ., viral genomes). In some aspects, the viral vectors are AAV vectors, ( / .< ., AAV viral genomes).Viral Particles
[0113] Also provided herein is a viral particle comprising the payload polynucleotide disclosed herein, the expression cassette disclosed herein, or the vector disclosed herein. Viral particles comprising the vectors ( / .< ., viral genomes, such as AAV viral genomes) disclosed herein are also provided for herein.
[0114] In some aspects, the viral particles disclosed herein are recombinant adeno-associated virus (rAAV) particles. In some aspects, the rAAV particles disclosed herein further comprise a capsid protein.
[0115] In some aspects, provided herein is a recombinant viral (AAV) particle comprising a capsid protein and a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7, andwherein the capsid protein is derived from an AAVrh74 capsid protein.
[0116] In some aspects, the rAAV particle comprises, or alternatively consists essentially of, or yet further consists of a capsid protein and a payload polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 8, wherein the capsid protein is derived from an AAVrh74 capsid protein.314917-7286-3658.7140056-10212025-039-03; 8216.WOOO Capsid Protein
[0117] In some aspects, the capsid protein is derived from AAVrh74 capsid protein. In some aspects, the capsid protein comprises, or alternatively consists essentially of, or yet further consists of an amino acid sequence having at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO: 9. In some aspects, the capsid protein comprises, or alternatively consists essentially of, or yet further consists of the amino acid sequence set forth in SEQ ID NO: 9.
[0118] In some aspects, the capsid protein is derived from AAVrh74 capsid protein. In some aspects, the capsid protein comprises, or alternatively consists essentially of, or yet further consists of an amino acid sequence having at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the sequence set forth in SEQ ID NO: 9. In some aspects, the capsid protein comprises, or alternatively consists essentially of, or yet further consists of the amino acid sequence set forth in SEQ ID NO: 9.
[0119] In some aspects, provided herein is a recombinant viral (e.g., AAV) particle comprising a capsid protein and a payload polynucleotide which comprises:(i) a 5’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 1;(ii) a MCK promoter comprising the nucleotide sequence set forth in SEQ ID NO: 2;(iii) an intron comprising the nucleotide sequence set forth in SEQ ID NO: 3;(iv) a nucleotide sequence encoding a human NT-3 polypeptide comprising the nucleotide sequence set forth in SEQ ID NO: 5;(v) an SV40 polyadenylation signal comprising the nucleotide sequence set forth in SEQ ID NO: 6; and(vi) a 3’ ITR comprising the nucleotide sequence set forth in SEQ ID NO: 7, andwherein the capsid protein comprises, or alternatively consists essentially of, or yet further consists of the amino acid sequence set forth in SEQ ID NO :9.
[0120] In some aspects, the rAAV particle comprises, or alternatively consists essentially of, or yet further consists of a capsid protein and a payload polynucleotide comprising the nucleotide sequence set forth in SEQ ID NO: 8, wherein the capsid protein comprises, or 324917-7286-3658.7140056-10212025-039-03; 8216.WOOO alternatively consists essentially of, or yet further consists of the amino acid sequence set forth in SEQ IDNO: 9.
[0121] The nucleic acid molecules and the vectors (e.g., AAV vectors) of the disclosure may be produced by any of the suitable means disclosed in the published literature. For example, the nucleic acid molecules may be produced by chemical synthesis or by recombinant DNA technology. Methods for producing recombinant AAV vectors are disclosed in the published literature (e.g., Kimura, T., Ferran, B., Tsukahara, Y. et al. Production of adeno-associated virus vectors for in vitro and in vivo applications. Sci Rep 9, 13601 (2019); Viral Vectors for Gene Therapy: Methods and Protocols, Manfredsson F.P, Benskey M.J., Springer Link (2019)).
[0122] The genetic code is well known in the published literature, and a person skilled in the art would be readily able to produce a nucleotide sequence encoding a defined amino acid sequence. Thus, a person skilled in the art, provided the amino acids sequence of, e.g., SEQ ID NO: 5, would be readily able to produce a nucleotide sequence encoding the same.
[0123] A person skilled in the art would know the that the four nucleotide bases of DNA: adenine (A), cytosine (C), guanine (G) and thymine (T) — can be used in various ways to spell out three-letter "codons" that specify which amino acid is needed at each position within a protein, and provided any amino acid sequence would be readily able to produce a nucleotide sequence encoding the same. A person skilled in the art would also know that a nucleotide sequence may vary due to the degeneracy of the genetic code. An exemplary representation of the genetic code is:2”^ base in codonC A G PS® W iy>- yu PR ?■<<■ cLssii S«s STOP AUo W i &te® R0 i His Vc Uss His AR c uUss Wft OH SR AU® Ro | Giss •AR GU A W i A®® Ssr UXS Thr Asa Ssr CR Tiir ..?« AW: AR G coVai Aia i As® UW Ais Asp Cvsi AS® i G& Giy AVai Aia | GH G334917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0124] Nevertheless, exemplary nucleotide sequences encoding a neurotrophin-3 (NT-3) of the disclosure are provided in the Sequence Table provided in the present disclosure. In some aspects, the NT-3 polypeptide is encoded by a nucleic acid sequence having at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity to the nucleic acid sequence set forth in SEQ ID NO: 5.Pharmaceutical Formulations
[0125] In some aspects, provided herein are pharmaceutical formulations comprising, or alternatively consisting essentially of, or yet further consisting of the nucleic acid molecules, or the vectors disclosed herein, and a pharmaceutically acceptable excipient, or pharmaceutically acceptable adjuvants, or any combination thereof.
[0126] In some aspects, the combination of the nucleic acid molecules or the vectors disclosed herein with one or more of the carriers described herein facilitates, enhances or enables administration of the nucleic acid molecules or the vectors disclosed herein to the subject. In some aspects, the combination of the nucleic acid molecules or the vectors disclosed herein with one or more of the carriers described herein facilitates, enhances or enables the delivery of the nucleic acid molecules or the vectors disclosed herein to a target cell. In some aspects, after administration to the subject of the nucleic acid molecules or the vectors disclosed herein, at least a portion of the nucleic acid molecules or the vectors disclosed herein are delivered to a target cell.Method of treatment and use
[0127] In some aspects, disclosed herein are methods of increasing the amount of neurotrophin-3 (NT-3) protein in a cell comprising, or alternatively consisting essentially of, or yet further consisting of contacting the cell with the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein.
[0128] In some aspects, the cell is a muscle cell. In some aspects, the muscle cell is derived from skeletal muscle or smooth muscle, e.g. from the digestive tract, urinary bladder, blood vessels or cardiac tissue. In some aspects, the muscle cell is a myoblast, a myocyte, a myotube, a cardiomyocyte, or a cardiomyoblast.
[0129] In some aspects, the cell is a mammalian cell. In some aspects, the cell is comprised in a subject. In some aspects, the subject suffers from one or more diseases, disorders, syndromes 344917-7286-3658.7140056-10212025-039-03; 8216.WOOO or conditions that can benefit from an increase in NT-3 protein expression and / or activity. In some aspects, the subject suffers from Charcot-Marie-Tooth (CMT). In some aspects, the disease subtype is selected from any one of CMT1A, CMT2A, CMT2D, or CMT1X.
[0130] In some aspects, the amount of NT-3 protein in the cell is increased of at least 0.1-fold, 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold compared to a same cell not administered the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein. In some aspects, disclosed herein are methods of treating a subject suffering from a diseases, disorders, syndromes or conditions that can benefit from an increase in neurotrophin-3 (NT-3) protein expression and / or activity. In some aspects, disclosed herein are methods of treating a subject suffering from a neuromuscular condition. In some aspects, the neuromuscular condition is Charcot-Marie-Tooth. In some aspects, disclosed herein are methods of treating a subject suffering from a neuropathy.
[0131] In some aspects, the methods disclosed herein comprise administering to the subject a therapeutically effective amount of the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein. The nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein may be administered to a subject in a single dose, or a multiple dose. In some aspects, the multiple dose comprises, or alternatively consists essentially of, or yet further consists of two, three, or four or more doses. In some aspects, the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein are administered to the subject at regular intervals, for example, weekly, biweekly, monthly, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, or yearly. In some aspects, the first set of doses (e.g., two, three, four, five, six, seven, eight or ten doses) are administered monthly, with further doses administered less frequently (e.g., every 3 months, every 6 months or yearly).
[0132] Administration can be by any suitable route, for example, administration can be systemic (e.g., intravenous) or local (e.g., to a muscle), or both.
[0133] In some aspects, the degeneration of myelinated neurons of the subject is reduced by at least 0.1-fold, 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold after administration of the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein. In some aspects, the neuron is a motor neuron, a peripheral neuron, or any combination thereof. In some aspects, the degeneration of myofibers of the subject is reduced by at least 0.1 -fold, 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold after administration of the nucleic acid molecules, the vectors, or the 354917-7286-3658.7140056-10212025-039-03; 8216.WOOO pharmaceutical formulations disclosed herein. In some aspects, a symptom of the neuromuscular condition or neuropathhy in the subject is reduced after administration of the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein. In some aspects, diseases, disorders, syndromes or conditions (e.g., a Charcot-Marie-Tooth disease, such as CMT1A, CMT1X, CMT2A, or CMT2D) is ameliorated or treated after administration of the nucleic acid molecules, the vectors, or the pharmaceutical formulations disclosed herein.EXAMPLESExample 1: Treatment of CMT1A in animal disease model
[0134] AAVrh74.NT3 gene therapy vectors were produced from the scAAVrh74.tMCK.NT-3 (SEQ ID NO: 12) and AAVrh74 Rep-Cap (SEQ ID NO: 11) plasmids prior to assessment of the therapeutic effects of administration. CMT1A model Trembler-J mice (aged approximately 6 to 9 weeks) were dosed via bilateral IM dosing as described in Example 2 at 1.57xlOnvg, 4.70xl0nvg, or 7.84xl011vg. The mice were euthanized and evaluated approximately 41 weeks post injection.TABLE 1 : Experimental design for in vivo treatment model studyStrain Group No. of Test / Control Article Route’ Ituse (vg)’’ Volume Terminal Animals / (uL) Time Point Sex (Weeks) Trembler-J 1 5-Tenntle Saline (Control) IM x'j / X 50 40 (WT)5 / Male2 5 •'Female Saline (Control ) IM N A 50 40 Trembler-J 5 / Male(Het)3 5 / Female AAVrh74 tMCK.NT-3 IM 1.57 IOB50 40(Test)< S / Female AAVrh74.tMCK.NT-3 IM 4.70 x 10u50 405 / Male { i CSt)5 5 Female AAVrh~4 tMCK.NT-3 IM 7.84 >• 10i!50 405. 'Male. (Test)
[0135] Circulating NT-3 protein levels were longitudinally evaluated using MSD as described in Example 2. Dose-dependent increases in NT-3 were observed at all assessed time points (FIG. 1). For each time point, the dose dependence was statistically significant with the364917-7286-3658.7140056-10212025-039-03; 8216.WOOO exception of Weeks 29 and 37, which did not show a statistically significant difference between the mid and high doses.
[0136] Gait analysis was performed approximately 38 weeks after dosing to assess kinematic characteristics indicative of motor skills and function. This analysis included assessment of hindlimb and distal forelimb joint angles at various points in the gait cycle as well as analysis of stride characteristics. The hind ankle angle was expected to show the most severe deficit of the joints and therefore be most sensitive to potential treatment effects. Trends of a positive NT-3 treatment effect, including a dose dependent improving trend in treated mice and a statistically significant effect at the highest dose tested, were observed (FIG. 2).
[0137] Histology analyses were performed on nerve sections to determine impacts of gene therapy. For Toluidine Blue staining of nerve sections, polymerized resin blocks containing fixed nerves were trimmed using a clean razor blade to remove any extraneous resin around the nerve. An ultramicrotome was then used to produce 1pm sections in ribbons. A ribbon of the sections was then placed on the end of a slide and dried and flattened using a hot plate. The semi-thin sections of nerves adhered to a glass slide were then stained with 1% Toluidine Blue in a 1% sodium borate solution for 20 seconds using a hot plate. After washing the stained sections thoroughly with water and allowing the slide to dry, brief washes were performed through a graded series of ethanol baths (70%, 95%, and 100% ethanol) followed by a brief xyline wash. After drying, a coverslip was added using Permount Mounting Medium. These coverslipped slides were then stored at room temperature. The coverslipped, Toluidine Blue stained nerve sections were imaged under brightfield using a 63X oil immersion objective (N.A. 1.4) and a widefield camera on a Stellaris 8 laser point scanning confocal system (Leica). One field of view was captured per tissue based on stain quality, high contrast between the nerves and background, and a lack of tissue artifacts. Generated images were stored in a secure repository. Nerve morphometry was analyzed in the proximal LSN by manual counts using the multipoint tool in Image J. Trained operators counted the number of visible axons in each of the following categories: Normally myelinated axons, hypomyelinated axons, unmyelinated axons, and degenerating axons. The main criterion for classifying an axon as degenerating was a dark dense cytoplasm. In addition, the number of axons with Schwann cells were counted. This was based on dark asymmetrical Toluidine Blue staining with a half moon shape, indicating the presence of the Schwann cell nucleus, enveloping an axon. Each of these values was expressed as a percentage of the total number of axons in the field of view.374917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0138] This histopathological analysis determined an improvement of disease phenotype with treatment of NT-3. Tr-J mice showed a severe defect, with widespread hypomyelination, demyelination, and degenerating axons, as well as marked Schwann cell recruitment compared to WT animals. Due to the severe phenotype of the Tr-J mice, the nerves were unable to be quantitated Gteocuvpby automated means. Manual counts including categorical counts of myelination and the percent wno sof axons with Schwann cells are tabulated in Table 3. Qualitative improvements were observed in the captured images, consistent with observations during histopathology that administration of doses of 4.70* 1011vg or higher was associated with modest decreases in the severity and incidence of myelin degeneration (FIG. 3).TABLE 2: Summary nerve manual count data\vv ,? <>:.<■kh w „S Shcwann S£ £ W >i WT .+.%) Sjl’.lK Me&J 044% 0 :A% 97.40% 0.93% 1.00% 3 rrenU'kr-J WT :%• ) Sate N A si; a •122% 7. •<<!% i 24% 054% 1 Trembler-? WT • SsiltJC STM (-.23% 0.15 % i.0?% 0.42% 0 ' J Trembler-.? WT SajjjFc a 4 4 4 4 4 > Traabier-’ H-st (Fr-.f-’-i SaihK Merm 5 43% ?$> 27% 904% ■<i,25% A Tiwflbto-J } v-.f Saline N / A SB 295% 2 31% 2 $:%• :< 0 22': ;> A Tieater-J f 1ST Th-J - Sj-rne N / A SEN ■ %% 5.41% 2. <30% 3.5 •%4 Treater-J nr-i -T) Sate N A ii 4 4 4 4 4
[0139] For neuromuscular junction (NMJ) analysis, samples were stained and imaged in the fixed and teased muscle fibers of the EDL. Samples were blocked in 10% normal goat serum + 0.1% Tween 20 in TBS, followed by incubation of the primary antibody solution for 2 hours at approximately 37°C. Primary antibodies included rabbit anti-Neurofilament light chain (Cell Signaling, 2837S, 1:200 dilution) and mouse anti-Synaptophysin (Dako / Agilent, M7315, 1:200 dilution) as well as an AlexaFluor™ 488 conjugated alpha bungarotoxin peptide (Invitrogen, B13422, 1:100 dilution) which was used to label acetylcholine receptors in the motor endplate. The samples were then washed in TBS 3 times for 20 minutes each. The secondary antibody cocktail was added for 2 hours at approximately 37°C. Secondary antibodies included goat antimouse AlexaFluor™ 687 (Invitrogen, A21236, 1:200 dilution) and goat anti-rabbit AlexaFluor™ 555 (Invitrogen, A21429, 1:200 dilution). The samples were then washed in TBS 3 times for 20 minutes each. 5 pg / mL DAPI was added for 3 minutes at room temperature, then samples were washed briefly with TBS. Samples were mounted with Vectashield Mounting Medium (Vector384917-7286-3658.7140056-10212025-039-03; 8216.WOOO Laboratories; Hl 00010) and stored at approximately -40°C until imaging. Imaging was performed using a Leica Stellaris 8 confocal microscope under a 20X air objective (N.A. 0.75). Imaging was performed as a Z-stack through the depth of the muscle fiber (ranging approximately 30 to 100 pm) in 0.685 pm increments in order to capture the full view of the NMJs, and this 3D reconstruction was used for analysis. Images presented in this report represent a maximum intensity projection of the 3D Z-stack. 3D images were analyzed using the NMJ Analyzer python package (v0.0.3) with some minor modifications. In brief, images were manually cropped, then thresholded and converted to binary images with the threshold intensity set to 8. These binary images were subject to concatenation and bordering to identify NMJs prior to feature extraction. The largest computed NMJ in the field of view was used for analysis. The parameters used for analysis were the volume, surface area, compactness, rugosity, and shape factor of the motor endplate. Compactness is a dimensionless value that describes the relationship between surface area and volume. It is calculated as (surface areaA1.5) / volume, such that a shape that maximizes the usable surface area for a given volume is considered more compact. The shape factor represents the ratio in volume between a sphere of equivalent radius and the actual measured volume of the complete neuromuscular junction. Increases in shape factor represent irregularities on the surface of the NMJ indicative of cellular degeneration.
[0140] Tr-J mice treated with saline showed significant reductions in endplate volume compared to WT animals and was significantly improved at the 4.70* 1011vg dose of AAVrh74.NT3 (FIG. 4A). Due to challenges with staining, fewer tissues with sufficient stain quality for quantitation were available in the 7.84* 1011vg dose group, reducing the power and potential for statistical significance vs the Trembler-J saline treated group. Measurements of surface area (FIGs. 10B, 10C) and rugosity (FIGs. 10E, 10F) exhibited the same trend as the endplate volume, with a statistically significant improvement at the 4.70* 1011vg dose. Though these parameters did not reach a statistically significant deficit in the untreated Tr-J animals due to the variability exhibited between animals, a clear trend was observed, with a separation between WT and saline treated Trembler-J animals and remediation with treatment of AAVrh74.NT3. NMJ compactness, a dimensionless value which describes the surface area per volume, was also calculated (FIG. 4D). An NMJ maximizing the surface area available for neurotransmitter exchange in a given volume is considered more compact. Compactness did not show a statistically significant difference between groups but trended similarly with the other factors, re-iterating the394917-7286-3658.7140056-10212025-039-03; 8216.WOOO change in morphometry of the NMJ in Trembler-J animals and remediating effect of AAVrh74.NT3.
[0141] This study demonstrated therapeutic efficacy of AAVrh74.NT3. Circulating NT-3 in blood serum showed a dose-dependent escalation and was sustained through the endpoint of the study (41 weeks post-dosing), indicating the durability of NT-3 expression. Tr-J mice administered doses of 4.70* 1011vg or above showed improvements to noted pathologies associated with CMT1A, such as gait deficits and altered NMJ morphometry. Particularly, the NMJ and nerve staining data (FIGs. 2, 3) suggested notable improvement of nerve function with treatment in a severe model of CMT1A. As such, similar treatment benefits could also be inferred for similar neuromuscular conditions that result in peripheral nerve demyelination and / or NMJ degradation, such as other subtypes of CMT.Example 2: Treatment of CMT2A in animal disease model
[0142] Having shown efficacious treatment of CMT1A and to further establish AAVrh74.NT3 as a broad-spectrum CMT therapy, the next step was to extend the study to additional diseases, particularly CMT2A, which is caused by mutations in the mitofusin 2 (MFN2) gene. Briefly, Mfn2+ / - conditional heterozygous mice were obtained using the Cre / Lox system by breeding homozygous Mfn2Lx / Lx (loxP-flanked exon 5 of Mfn2 gene) and homozygous nestin-Cre (Cre+ / +) mice, in which the Nestin promotor allows Cre recombinase expression in the central and peripheral nervous system. The Mfn2Lx / -;Cre+ / - (Mfn2+ / -), mouse is heterozygous for Mfn2 deletion. Eight-month-old Mfn2+ / - mice received a 3xl0nvg intramuscular dose of AAVrh74.NT3. Age- and sex-matched Mfn2+ / - mice received Ringer’s lactate and served as untreated (UT) controls (n=12 for both cohorts, with equal sex distribution). Mice were sacrificed six months post injection.
[0143] Rotarod and grip strength functional tests and electrophysiological measurements were performed at baseline (BL) and endpoint (EP). Peripheral nerves, innervation status of NMJs, and skeletal muscles were also assessed with morphometric studies. Serum NT-3 levels detected by ELISA confirmed that therapeutic levels were attained in the treated cohort (5.76 ± 0.65 ng / ml, FIG. 5).
[0144] Grip strength and rotarod functional assays showed that NT-3 treated mice performed significantly better than the untreated mice by 23.9% and 24.5%, respectively, at endpoint (grip strength, NT-3: 0.109± 0.004 vs UT: 0.088 ± 0.004, p=0.0014; rotarod, NT-3: 26.17404917-7286-3658.7140056-10212025-039-03; 8216.WOOO ± 1.3s vs UT: 21.11 ± 1.7 s, p=0.0373, FIGs. 12A, 12B). Electrophysiologic studies showed significant improvements in both compound muscle action potential (CMAP) and nerve conduction velocity (NCV) in the NT-3-treated group (FIGs. 12C, 12D). Treated mice had significantly higher CMAP (by 16.4%) and NCV (by 27.6%) values at the endpoint compared to untreated Mfn2+ / - mice (CMAP: NT-3: 49.54 ± 1.19 vs UT: 42.55 ± 1.45 mV, pO.OOOl; NCV: NT-3: 47.75 ± 3.34 vs UT: 37.42 ± 2.50 m / s, p= 0.0089).
[0145] Histologic studies on the sciatic nerve were conducted as previously described and showed the presence of myelin alterations, such as myelin corrugation, inpouching and outpouching compatible with axonal shrinkage in the untreated Mfn2+ / - mice, which were notably reduced with treatment (FIGs. 7A, 7B). Morphometric analysis on sciatic nerve revealed that total number of myelinated fibers (MF) were not altered significantly in the Mfn2+ / - mice compared to wild type (Table 4), though a shift towards smaller fiber size was observed with NT-3 treatment, resulting in a significant increase in the number of myelinated fibers with small (<4pm diameter) axons (FIG. 7C). Analysis of NMJs also showed a significant increase in the percent of innervated NMJs in the treated mice, compared to untreated counterparts, in the lumbrical muscles (FIG. 8).TABLE 3: Total myelinated fibers (MF) in various cohortsCohort Untreated NT-3 WT Total number MF 1905.7±39.1 1980.8±97.7 1997.6±41.9
[0146] Turning to the muscle tissue, succinate dehydrogenase (SDH) / cytochrome c oxidase (COX) staining was performed to assess metabolic health of various muscle fibers. The analysis revealed an increase in fibers with abnormal mitochondria content and distribution (FIGs.9A, 9B). Measurements on SDH-stained tibialis anterior (FIG. 9A) and gastrocnemius (FIG. 9B) muscles showed that number of abnormal fibers were significantly reduced in the NT-3 treated mice compared to untreated counterparts, in both muscles (GAS, NT-3: 6.79 ± 1.04 number / mm2 vs UT: 21.41 ± 3.80 number / mm2, p=0.004; TA, NT-3: 5.57 ± 0.58 number / mm2vs UT: 12.53 ± 1.68 number / mm2, p=0.003). Next, oxidative stress levels in gastrocnemius muscle were assessed using a 3 -Nitrotyrosine (3-NT) ELISA assay. The results showed that untreated mice had significantly higher 3-NT levels than WT (UT: 177.5 ± 7.9 ng / mL vs WT: 90.0 ± 9.8 ng / mL,414917-7286-3658.7140056-10212025-039-03; 8216.WOOO p=0.0002) and that oxidative stress levels were normalized in the treated cohort (NT-3: 114.17 ± 12.14 ng / mL) (FIG. 9C).
[0147] Collectively, these results demonstrated the efficacy of treating CMT2A with AAVrh74.NT3. Notably, treatment resulted in therapeutic serum NT-3 levels and improvements in functional, electrophysiological, and histological improvements with significantly reduced oxidative stress in muscle. As such, this gene therapy was established as a broad-spectrum therapy capable of reducing symptoms associated with various neuromuscular conditions.
[0148] It is understood that the examples and aspects described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.SEQUENCE TABLETable 4: Exemplary sequences of the present disclosureSEQ ID NO DESCRIPTION SEQUENCE1 5 ' ITR CAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGC CCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGA GCGAGCGCGCAGAGAGGGAGTGG2 tMCK GGTTAACCAATTGGCGGCCGCAAACTTGCATGCCCCACTACGG promoter GTCTAGGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCG AGATGCCTGGTTATAATTAACCCCAACACCTGCTGCCCCCCCC CCCCCAACACCTGCTGCCTGAGCCTGAGCGGTTACCCCACCCC GGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTC GCTCTAAAAATAACCCTGTCCCTGGTGGATCCACTACGGGTCT ATGCTGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGAT GCCTGGTTATAATTAACCCCAACACCTGCTGCCCCCCCCCCCC CAACACCTGCTGCCTGAGCCTGAGCGGTTACCCCACCCCGGTG CCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTC TAAAAATAACCCTGTCCCTGGTGGACCACTACGGGTCTAGGCT GCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGATGCCTG GTTATAATTAACCCCAACACCTGCTGCCCCCCCCCCCCAACAC CTGCTGCCTGAGCCTGAGCGGTTACCCCACCCCGGTGCCTGGG TCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAA TAACCCTGTCCCTGGTCCTCCCTGGGGACAGCCCCTCCTGGCT AGTCACACCCTGTAGGCTCCTCTATATAACCCAGGGGCACAGGGGCTGCCCCCGGGTCAC424917-7286-3658.7140056-10212025-039-03; 8216.WOOO 3 Chimeric GTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGA intron AACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATA GGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCC ACAG5 NT- 3 ATGTCCATCTTGTTTTATGTGATATTTCTCGCTTATCTCCGTG transgene GCATCCAAGGTAACAACATGGATCAAAGGAGTTTGCCAGAAGA CTCGCTCAATTCCCTCATTATTAAGCTGATCCAGGCAGATATT TTGAAAAACAAGCTCTCCAAGCAGATGGTGGACGTTAAGGAAA ATTACCAGAGCACCCTGCCCAAAGCTGAGGCTCCCCGAGAGCC GGAGCGGGGAGGGCCCGCCAAGTCAGCATTCCAGCCGGTGATT GCAATGGACACCGAACTGCTGCGACAACAGAGACGCTACAACT CACCGCGGGTCCTGCTGAGCGACAGCACCCCCTTGGAGCCCCC GCCCTTGTATCTCATGGAGGATTACGTGGGCAGCCCCGTGGTG GCGAACAGAACATCACGGCGGAAACGGTACGCGGAGCATAAGA GTCACCGAGGGGAGTACTCGGTATGTGACAGTGAGAGTCTGTG GGTGACCGACAAGTCATCGGCCATCGACATTCGGGGACACCAG GTCACGGTGCTGGGGGAGATCAAAACGGGCAACTCTCCCGTCA AACAATATTTTTATGAAACGCGATGTAAGGAAGCCAGGCCGGT CAAAAACGGTTGCAGGGGTATTGATGATAAACACTGGAACTCT CAGTGCAAAACATCCCAAACCTACGTCCGAGCACTGACTTCAG AGAACAATAAACTCGTGGGCTGGCGGTGGATACGGATAGACAC GTCCTGTGTGTGTGCCTTGTCGAGAAAAATCGGAAGAACATGA6 Poly (A) GATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCA sequence C AACTAG AATG CAGTGAAAAAAATG CTTTATTTGTAAAATTTG TGATG CTATTG CTTTATTTGTAACC ATTATAAG CTGC AATAAA CAAGTT7 3 ' ITR AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGC TCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGC CCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGC8 SCAAVrh74 . tM CAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGC CK.NT3 CCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGA GCGAGCGCGCAGAGAGGGAGTGGGGTTAACCAATTGGCGGCCG CAAACTTGCATGCCCCACTACGGGTCTAGGCTGCCCATGTAAG GAGGCAAGGCCTGGGGACACCCGAGATGCCTGGTTATAATTAA CCCCAACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTG AGCCTGAGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTC TGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTC CCTGGTGGATCCACTACGGGTCTATGCTGCCCATGTAAGGAGG CAAGGCCTGGGGACACCCGAGATGCCTGGTTATAATTAACCCC AACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTGAGCC TGAGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTA CACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTG GTGGACCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGG CCTGGGGACACCCGAGATGCCTGGTTATAATTAACCCCAACAC CTGCTGCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTGAGCG GTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCAT GGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTGGTCCTC CCTGGGGACAGCCCCTCCTGGCTAGTCACACCCTGTAGGCTCC TCTATATAACCCAGGGGCACAGGGGCTGCCCCCGGGTCACCTG CAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTT ACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCT434917-7286-3658.7140056-10212025-039-03; 8216.WOOO TACTGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCC CAGTTCAATTACAGCGCGTGGTACCTGCAGGGATATCCACCAT GTCCATCTTGTTTTATGTGATATTTCTCGCTTATCTCCGTGGC ATCCAAGGTAACAACATGGATCAAAGGAGTTTGCCAGAAGACT CGCTCAATTCCCTCATTATTAAGCTGATCCAGGCAGATATTTT GAAAAACAAGCTCTCCAAGCAGATGGTGGACGTTAAGGAAAAT TACCAGAGCACCCTGCCCAAAGCTGAGGCTCCCCGAGAGCCGG AGCGGGGAGGGCCCGCCAAGTCAGCATTCCAGCCGGTGATTGC AATGGACACCGAACTGCTGCGACAACAGAGACGCTACAACTCA CCGCGGGTCCTGCTGAGCGACAGCACCCCCTTGGAGCCCCCGC CCTTGTATCTCATGGAGGATTACGTGGGCAGCCCCGTGGTGGC GAACAGAACATCACGGCGGAAACGGTACGCGGAGCATAAGAGT CACCGAGGGGAGTACTCGGTATGTGACAGTGAGAGTCTGTGGG TGACCGACAAGTCATCGGCCATCGACATTCGGGGACACCAGGT CACGGTGCTGGGGGAGATCAAAACGGGCAACTCTCCCGTCAAA CAATATTTTTATGAAACGCGATGTAAGGAAGCCAGGCCGGTCA AAAACGGTTGCAGGGGTATTGATGATAAACACTGGAACTCTCA GTGCAAAACATCCCAAACCTACGTCCGAGCACTGACTTCAGAG AACAATAAACTCGTGGGCTGGCGGTGGATACGGATAGACACGT CCTGTGTGTGTGCCTTGTCGAGAAAAATCGGAAGAACATGAGG CGGCCGCGGGGATCCAGACATGATAAGATACATTGATGAGTTT GGACAAACC AC AACTAG AATG CAGTGAAAAAAATG CTTTATTT GTAAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAG CTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATG TTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTCGGCGCGCC TCTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATC ATTAACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCT CTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGT CGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAG CGAGCGCGC9 AAVrh74 MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDNGR capsid GLVLPGYKYLGPFNGLDKGEPVNAADAAALEHDKAYDQQLQAG protein DNP YLRYNHADAE FQERLQEDTS FGGNLGRAVFQAKKRVLE PL GLVES PVKTAPGKKR PVE PS PQRS PDS STG I GKKGQQ PAKKRL NFGQTGDSESVPDPQPIGEPPAGPSGLGSGTMAAGGGAPMADN NEG ADGVGS S S GNWH CDS TWLGDRV I TTS TRTWAL PT YNNHL Y KQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQR L INNNWG FR PKRLNFKL FN I QVKEVTQNEGTKT I ANNLTST I Q VFTDSEYQLPYVLGSAHQGCLPPFPADVFMI PQYGYLTLNNGS QAVGRSSFYCLEYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHS QSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPNNM SAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGR DSLVNPGVAMATHKDDEERFFPSSGVLMFGKQGAGKDNVDYSS VMLTS EEE I KTTNPVATEQ YG WADNLQQQNAAP I VGAVNS QG ALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHP P PQ I L I KNTPVPADP PTTFNQAKLAS F I TQYSTGQVS VE I EWE LQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPIGT RYLTRNL10 AAV1 Rep / Cap cgggccccccctcgaggtcgacggtatcgggggagctcgcagggtctccattttg plasmid aagcgggaggtttgaacgcgcagccgccatgccggggttttacgagattgtgatta aggtccccagcgaccttgacgagcatctgcccggcatttctgacagctttgtgaactgggtggccgagaaggaatgggagttgccgccagattctgacatggatctgaatct 444917-7286-3658.7140056-10212025-039-03; 8216.WOOO gattgagcaggcacccctgaccgtggccgagaagctgcagcgcgactttctgacg gaatggcgccgtgtgagtaaggccccggaggctcttttctttgtgcaatttgagaag ggagagagctacttccacatgcacgtgctcgtggaaaccaccggggtgaaatcca tggttttgggacgtttcctgagtcagattcgcgaaaaactgattcagagaatttaccg cgggatcgagccgactttgccaaactggttcgcggtcacaaagaccagaaatggc gccggaggcgggaacaaggtggtggatgagtgctacatccccaattacttgctcc ccaaaacccagcctgagctccagtgggcgtggactaatatggaacagtatttaagc gcctgtttgaatctcacggagcgtaaacggttggtggcgcagcatctgacgcacgt gtcgcagacgcaggagcagaacaaagagaatcagaatcccaattctgatgcgcc ggtgatcagatcaaaaacttcagccaggtacatggagctggtcgggtggctcgtg gacaaggggattacctcggagaagcagtggatccaggtgagtaattgacaaagcc aaacaccaccatttgccgagcactttagagtttacaggtttgtttctcttgaccctcaa aacaaacctgtgaggcatagggagtattgctatcccttaagaattcacccccagtgt gcccatcaaaacctcccaggctgagtctgcacagttgaaggaggaaggatagga atgggagggtcgatgggtgaaagcatgattctcttaaccagtccagattatcaggta atcccttcaacaaccaccacccactccctgggcaatccagctggagtttacagaca gacttagctggctatagcaccaccgtgctactctctgttcttcctggttgctcaaatgc cctagaaaagtggaacaggtgagcatcaactcacagggctctatgctggctgctgc tgcgagggatgttatgctatagtaccaggggccaccattccataggcacttcctgtg tttaataccctatatgctttacttcatctcatcttcctccatatcctgagaggtggttctatt cttctccccattttacggatgaaaaaaccgagacacagaaaggtgaaatagcttaag ataaatggtgccttgcagccttagactctggtggcctctagttaatgtgggaaattaa gggtgaggggattggcagctgatggagggtgcagggtgccagacagaggcgttt agctctgatcccttagcaatagagagtccttgtaggcacttggtcaggcgagtgatg cgatgaaagctgtgtttaagaaagattatgctttctgctgatttcatacccccaacacc caagctctgaggcccctcctcacaggtccttgcagggctggccaaaataaagcag cttcactccgttgtgctgctttccagctaatgtgtctgtttggcagaagtttccctcaaa ggcagatcagtgaaataagcagaagcctcgacccccctttgtcagccagagctgc tgaagtgccttgccccagggtcactttgtgtgaggggattagagagcactggggct gccaagaaacactgccgtttctacagattagcaggacgctggcttgtggccttctag cgaggctcagagctgcggtggccctagtctgcatgggctaaagacaagctccatc tcctgtccttgttccctccttcctgggcacagccgccctgcttcttggttctctctgttg gttcctgtccgcacggtagttaggctggcagcgtgtgtaggatttggcttagaagatt gacaacattgcctttgagcccttctttgctactcctccctctcccctcccatcagactc ctctctggagtctgctctgcgaggcctctgctctgtggtatcccagcagccttctcag ccttgacttccagaagggggctgtgcagtgtccggggtgtgcaggccccagacac ggggtaggctcatggagatccaagtgctgatctagtgtcaaggctggcctggaga ctgggctgggttggtgtctgcctgctgtggtcatgtgccctcccttgggcctgtatcc tctctccagacttgctgcagggagaggtggcagatgtcagcctagttctggcctctc agagcagcatggcagctccctttcactcaggcccaggctgggccctcctgctggct gacccctggggagagggtgctccagagctccccaaggaacagcttcccgaagca gccaggccagcccagaggggctgtggccaatcctgaagctttatgttcctgctgac attttttctaagttttctcttgctttcctcttaaatgccaatctggagagtctccgttagga gaaatggaccccagccaggaagaagagttgagttgtatttaaaacacgagctccc cctaaagcatccttctttagcttctaaggagaggcagagactgacaggcaggactc agcaggaaaaggtacccccctgacctgctcagtcaggccctaggcccagctccacccagcctgtggcccccagagtttcggtaaagagttccctgggccttaaggaacct454917-7286-3658.7140056-10212025-039-03; 8216.WOOO tgagagagcatttgaggggtgccaccacaaacttggcagaaaaaaccctccccct ccaagtccagtcctagagaaggagctggcaaccttgccttgctttgtaagcaaaag cctcttagggcttgagctcagatgtagtgtttgagctgtggctggtgccctgccccat cagggagccaatggtagacatcctatgggcatctttgttttccgtaagagcaggctg tctggggatgggccagaggaagaggcgacctggagtcaaccaagaggaggcct taaccaagccttaaccacagaggttaaccaagccttgaaagcgcttccccctgagc aggcaggaagcactgagtccacatggttgcctcgctgtttcatttccttacactcaatt ctctcagtctttaaatgatcacttggccttgaagttacggatatttggggtctgaactga agttgaagaaaagaggaaatgatttaagctttgtttaagattaggggccaggtgcgg tggctcacgcctgtaatcccagcaccttgggagcctgaggcgggtggatcacctg aggtcaggagttccagaccagcctggccaacatagcaaaacccagtctctactaa aaataacaataaaaaaattagccaggtgtggtgacacatgcctgtaatcccagttac tcaggaggctgaggcagaattgcttgaacttgagaggtggaggttgtagtgagcca agaccgcaccactgcactccagcctggcgacagagccagactccgtctcaaaaa caacaacaaaaaagattagaagaagcccattactgccttctggccacccactcgca cagacaccaaaactgcagcccacacctcgccatcctcgtgctctgccctgggaca ccccaggcacagtgtgtccttcgttttctgtaagggtgggctgggagcagggacgg acagggcctgtgggcacctctcatggtcacttccttcttgctcacaggaggaccag gcctcatacatctccttcaatgcggcctccaactcgcggtcccaaatcaaggctgcc ttggacaatgcgggaaagattatgagcctgactaaaaccgcccccgactacctggt gggccagcagcccgtggaggacatttccagcaatcggatttataaaattttggaact aaacgggtacgatccccaatatgcggcttccgtctttctgggatgggccacgaaaa agttcggcaagaggaacaccatctggctgtttgggcctgcaactaccgggaagac caacatcgcggaggccatagcccacactgtgcccttctacgggtgcgtaaactgg accaatgagaactttcccttcaacgactgtgtcgacaagatggtgatctggtgggag gaggggaagatgaccgccaaggtcgtggagtcggccaaagccattctcggagg aagcaaggtgcgcgtggaccagaaatgcaagtcctcggcccagatagacccgac tcccgtgatcgtcacctccaacaccaacatgtgcgccgtgattgacgggaactcaa cgaccttcgaacaccagcagccgttgcaagaccggatgttcaaatttgaactcacc cgccgtctggatcatgactttgggaaggtcaccaagcaggaagtcaaagactttttc cggtgggcaaaggatcacgtggttgaggtggagcatgaattctacgtcaaaaagg gtggagccaagaaaagacccgcccccagtgacgcagatataagtgagcccaaac gggtgcgcgagtcagttgcgcagccatcgacgtcagacgcggaagcttcgatca actacgcagacaggtaccaaaacaaatgttctcgtcacgtgggcatgaatctgatg ctgtttccctgcagacaatgcgagagaatgaatcagaattcaaatatctgcttcactc acggacagaaagactgtttagagtgctttcccgtgtcagaatctcaacccgtttctgt cgtcaaaaaggcgtatcagaaactgtgctacattcatcatatcatgggaaaggtgcc agacgcttgcactgcctgcgatctggtcaatgtggatttggatgactgcatctttgaa caataaatgatttAAATCAGGTATGGCTGCCGATGGTTAT CTTCCAGATTGGCTCGAGGACAACCTCTCTGAGGG CATTCGCGAGTGGTGGGACTTGAAACCTGGAGCC CCGAAGCCCAAAGCCAACCAGCAAAAGCAGGACG ACGGCCGGGGTCTGGTGCTTCCTGGCTACAAGTAC CTCGGACCCTTCAACGGACTCGACAAGGGGGAGC CCGTCAACGCGGCGGACGCAGCGGCCCTCGAGCA CGACAAGGCCTACGACCAGCAGCTCAAAGCGGGTGACAATCCGTACCTGCGGTATAACCACGCCGACG464917-7286-3658.7140056-10212025-039-03; 8216.WOOO CCGAGTTTCAGGAGCGTCTGCAAGAAGATACGTCT TTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGC CAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTG AGGAAGGCGCTAAGACGGCTCCTGGAAAGAAACG TCCGGTAGAGCAGTCGCCACAAGAGCCAGACTCC TCCTCGGGCATCGGCAAGACAGGCCAGCAGCCCG CTAAAAAGAGACTCAATTTTGGTCAGACTGGCGA CTCAGAGTCAGTCCCCGATCCACAACCTCTCGGAG AACCTCCAGCAACCCCCGCTGCTGTGGGACCTACT ACAATGGCTTCAGGCGGTGGCGCACCAATGGCAG ACAATAACGAAGGCGCCGACGGAGTGGGTAATGC CTCAGGAAATTGGCATTGCGATTCCACATGGCTGG GCGACAGAGTCATCACCACCAGCACCCGCACCTG GGCCTTGCCCACCTACAATAACCACCTCTACAAGC AAATCTCCAGTGCTTCAACGGGGGCCAGCAACGA CAACCACTACTTCGGCTACAGCACCCCCTGGGGGT ATTTTGATTTCAACAGATTCCACTGCCACTTTTCAC CACGTGACTGGCAGCGACTCATCAACAACAATTG GGGATTCCGGCCCAAGAGACTCAACTTCAAACTCT TCAACATCCAAGTCAAGGAGGTCACGACGAATGA TGGCGTCACAACCATCGCTAATAACCTTACCAGCA CGGTTCAAGTCTTCTCGGACTCGGAGTACCAGCTT CCGTACGTCCTCGGCTCTGCGCACCAGGGCTGCCT CCCTCCGTTCCCGGCGGACGTGTTCATGATTCCGC AATACGGCTACCTGACGCTCAACAATGGCAGCCA AGCCGTGGGACGTTCATCCTTTTACTGCCTGGAAT ATTTCCCTTCTCAGATGCTGAGAACGGGCAACAAC TTTACCTTCAGCTACACCTTTGAGGAAGTGCCTTT CCACAGCAGCTACGCGCACAGCCAGAGCCTGGAC CGGCTGATGAATCCTCTCATCGACCAATACCTGTA TTACCTGAACAGAACTCAAAATCAGTCCGGAAGT GCCCAAAACAAGGACTTGCTGTTTAGCCGTGGGTC TCCAGCTGGCATGTCTGTTCAGCCCAAAAACTGGC TACCTGGACCCTGTTATCGGCAGCAGCGCGTTTCT AAAACAAAAACAGACAACAACAACAGCAATTTTA CCTGGACTGGTGCTTCAAAATATAACCTCAATGGG CGTGAATCCATCATCAACCCTGGCACTGCTATGGC CTCACACAAAGACGACGAAGACAAGTTCTTTCCC ATGAGCGGTGTCATGATTTTTGGAAAAGAGAGCG CCGGAGCTTCAAACACTGCATTGGACAATGTCATG ATTACAGACGAAGAGGAAATTAAAGCCACTAACC CTGTGGCCACCGAAAGATTTGGGACCGTGGCAGT CAATTTCCAGAGCAGCAGCACAGACCCTGCGACC GGAGATGTGCATGCTATGGGAGCATTACCTGGCAT GGTGTGGCAAGATAGAGACGTGTACCTGCAGGGT CCCATTTGGGCCAAAATTCCTCACACAGATGGACACTTTCACCCGTCTCCTCTTATGGGCGGCTTTGGACT474917-7286-3658.7140056-10212025-039-03; 8216.WOOO CAAGAACCCGCCTCCTCAGATCCTCATCAAAAAC ACGCCTGTTCCTGCGAATCCTCCGGCGGAGTTTTC AGCTACAAAGTTTGCTTCATTCATCACCCAATACT CCACAGGACAAGTGAGTGTGGAAATTGAATGGGA GCTGCAGAAAGAAAACAGCAAGCGCTGGAATCCC GAAGTGCAGTACACATCCAATTATGCAAAATCTGC CAACGTTGATTTTACTGTGGACAACAATGGACTTT ATACTGAGCCTCGCCCCATTGGCACCCGTTACCTT ACCCGTCCCCTGTAATTACATGTTAATCAATAAAC CGGTTAATTCGTTTCAGTTGAACTTTGGTCTCCTGT CCTTCTTATCTTATCGGTTACCATAGAAACTGGTT ACTTATTAACTGCTTGGTGCGCTTCGCGATAAAAG ACTTACGTCATCGGGTTACCCCTAGTGATGGAGCg gccgctttcagttgaactttggtctctgcgtatttctttcttatctagtttccatgctctaga ggtcctgtattagaggtcacgtgagtgttttgcgacattttgcgacaccatgtggtca cgctgggtatttaagcccgagtgagcacgcagggtctccattttgaagcgggaggt ttgaacgcgcagccgccaagccgaattctgcagataattccgtgtattctatagtgtc acctaaatcgtatgtgtatgatacataaggttatgtattaattgtagccgcgttctaacg acaatatgtacaagcctaattgtgtagcatctggcttactgaagcagaccctatcatct ctctcgtaaactgccgtcagagtcggtttggttggacgaaccttctgagtttctggtaa cgccgtcccgcacccggaaatggtcagcgaaccaatcagcagggtcatcgctag ccagatcctctacgccggacgcatcgtggccggcatcaccggcgccacaggtgc ggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcgccac ttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccgcccTCAG AAGAACTCGTCAAGAAGGCGATAGAAGGCGATGC GCTGCGAATCGGGAGCGGCGATACCGTAAAGCAC GAGGAAGCGGTCAGCCCATTCGCCGCCAAGCTCTT CAGCAATATCACGGGTAGCCAACGCTATGTCCTGA TAGCGGTCCGCCACACCCAGCCGGCCACAGTCGA TGAATCCAGAAAAGCGGCCATTTTCCACCATGATA TTCGGCAAGCAGGCATCGCCATGGGTCACGACGA GATCCTCGCCGTCGGGCATGCGCGCCTTGAGCCTG GCGAACAGTTCGGCTGGCGCGAGCCCCTGATGCTC TTCGTCCAGATCATCCTGATCGACAAGACCGGCTT CCATCCGAGTACGTGCTCGCTCGATGCGATGTTTC GCTTGGTGGTCGAATGGGCAGGTAGCCGGATCAA GCGTATGCAGCCGCCGCATTGCATCAGCCATGATG GATACTTTCTCGGCAGGAGCAAGGTGGGATGACA GGAGATCCTGCCCCGGCACTTCGCCCAATAGCAG CCAGTCCCTTCCCGCTTCAGTGACAACGTCGAGCA CAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCA CGATAGCCGCGCTGCCTCGTCCTGCAGTTCATTCA GGGCACCGGACAGGTCGGTCTTGACAAAAAGAAC CGGGCGCCCCTGCGCTGACAGCCGGAACACGGCG GCATCAGAGCAGCCGATTGTCTGTTGTGCCCAGTC ATAGCCGAATAGCCTCTCCACCCAAGCGGCCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGCG484917-7286-3658.7140056-10212025-039-03; 8216.WOOO AAACGATCCTCATCCTGTCTCTTGATCAGATCTTG ATCCCCTGCGCCATCAGATCCTTGGCGGCAAGAAA GCCATCCAGTTTACTTTGCAGGGCTTCCCAACCTT ACCAGAGGGCGCCCCAGCTGGCAATTCCGGaacaccc cttgtattactgtttatgtaagcagacagttttattgttcatgatgatatatttttatcttgtg caatgtaacatcagagattttgagacacaacgtggtttgcaggagtcaggcaactat ggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggt aactgtcagaccaagtttactcatatatactttagattgatttaaaacttcatttttaattta aaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaacgtga gttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagat cctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcgg tggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagc agagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttca agaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgc tgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccgg ataaggcgcagcggtcgggctgaacggggggttcgtgcacacagcccagcttgg agcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcg ccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtc ggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttat agtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcagg ggggcggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggcc ttttgctggccttttgctcacatgttctttcctgcgttatcccctgattctgtggataaccg tattaccgcctttgagtgagctgataccgctcgccgcagccgaacgaccgagcgc agcgagtcagtgagcgaggaagcggaagagcgcccaatacgcaaaccgcctct ccccgcgcgttggccgattcattaatgcagctgtggaatgtgtgtcagttagggtgt ggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaatt agtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgc aaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcc cgcccctaactccgcccagttccgcccattctccgccccatggctgactaatttttttt atttatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgagg aggcttttttggaggaacaaacagcttttttggggtgaacatattgactgaattggcg aacgtggcgagaaaggaagggaagaaagcgaaaggagcgggcgctagggcg ctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatg cgccgctacagggcgcgtcccattcgccattcaggctgcgcaactgttgggaagg gcgatcggtgcgggcctcttcgctattacgccagctggcgaaagggggatgtgct gcaaggcgattaagttgggtaacgccagggttttcccagtcacgacgttgtaaaac gacggccagtgagcgcgcgtaatacgactcactatagggcgaattgggtac 11 AAVrh74 cgggccccccctcgaggtcgacggtatcgggggagctcgcagggtctccattttg Rep / Cap aagcgggaggtttgaacgcgcagccgccatgccggggttttacgagattgtgatta plasmid aggtccccagcgaccttgacgagcatctgcccggcatttctgacagctttgtgaact gggtggccgagaaggaatgggagttgccgccagattctgacatggatctgaatct gattgagcaggcacccctgaccgtggccgagaagctgcagcgcgactttctgacg gaatggcgccgtgtgagtaaggccccggaggctcttttctttgtgcaatttgagaag ggagagagctacttccacatgcacgtgctcgtggaaaccaccggggtgaaatcca tggttttgggacgtttcctgagtcagattcgcgaaaaactgattcagagaatttaccg cgggatcgagccgactttgccaaactggttcgcggtcacaaagaccagaaatggcgccggaggcgggaacaaggtggtggatgagtgctacatccccaattacttgctcc494917-7286-3658.7140056-10212025-039-03; 8216.WOOO ccaaaacccagcctgagctccagtgggcgtggactaatatggaacagtatttaagc gcctgtttgaatctcacggagcgtaaacggttggtggcgcagcatctgacgcacgt gtcgcagacgcaggagcagaacaaagagaatcagaatcccaattctgatgcgcc ggtgatcagatcaaaaacttcagccaggtacatggagctggtcgggtggctcgtg gacaaggggattacctcggagaagcagtggatccaggtgagtaattgacaaagcc aaacaccaccatttgccgagcactttagagtttacaggtttgtttctcttgaccctcaa aacaaacctgtgaggcatagggagtattgctatcccttaagaattcacccccagtgt gcccatcaaaacctcccaggctgagtctgcacagttgaaggaggaaggatagga atgggagggtcgatgggtgaaagcatgattctcttaaccagtccagattatcaggta atcccttcaacaaccaccacccactccctgggcaatccagctggagtttacagaca gacttagctggctatagcaccaccgtgctactctctgttcttcctggttgctcaaatgc cctagaaaagtggaacaggtgagcatcaactcacagggctctatgctggctgctgc tgcgagggatgttatgctatagtaccaggggccaccattccataggcacttcctgtg tttaataccctatatgctttacttcatctcatcttcctccatatcctgagaggtggttctatt cttctccccattttacggatgaaaaaaccgagacacagaaaggtgaaatagcttaag ataaatggtgccttgcagccttagactctggtggcctctagttaatgtgggaaattaa gggtgaggggattggcagctgatggagggtgcagggtgccagacagaggcgttt agctctgatcccttagcaatagagagtccttgtaggcacttggtcaggcgagtgatg cgatgaaagctgtgtttaagaaagattatgctttctgctgatttcatacccccaacacc caagctctgaggcccctcctcacaggtccttgcagggctggccaaaataaagcag cttcactccgttgtgctgctttccagctaatgtgtctgtttggcagaagtttccctcaaa ggcagatcagtgaaataagcagaagcctcgacccccctttgtcagccagagctgc tgaagtgccttgccccagggtcactttgtgtgaggggattagagagcactggggct gccaagaaacactgccgtttctacagattagcaggacgctggcttgtggccttctag cgaggctcagagctgcggtggccctagtctgcatgggctaaagacaagctccatc tcctgtccttgttccctccttcctgggcacagccgccctgcttcttggttctctctgttg gttcctgtccgcacggtagttaggctggcagcgtgtgtaggatttggcttagaagatt gacaacattgcctttgagcccttctttgctactcctccctctcccctcccatcagactc ctctctggagtctgctctgcgaggcctctgctctgtggtatcccagcagccttctcag ccttgacttccagaagggggctgtgcagtgtccggggtgtgcaggccccagacac ggggtaggctcatggagatccaagtgctgatctagtgtcaaggctggcctggaga ctgggctgggttggtgtctgcctgctgtggtcatgtgccctcccttgggcctgtatcc tctctccagacttgctgcagggagaggtggcagatgtcagcctagttctggcctctc agagcagcatggcagctccctttcactcaggcccaggctgggccctcctgctggct gacccctggggagagggtgctccagagctccccaaggaacagcttcccgaagca gccaggccagcccagaggggctgtggccaatcctgaagctttatgttcctgctgac attttttctaagttttctcttgctttcctcttaaatgccaatctggagagtctccgttagga gaaatggaccccagccaggaagaagagttgagttgtatttaaaacacgagctccc cctaaagcatccttctttagcttctaaggagaggcagagactgacaggcaggactc agcaggaaaaggtacccccctgacctgctcagtcaggccctaggcccagctcca cccagcctgtggcccccagagtttcggtaaagagttccctgggccttaaggaacct tgagagagcatttgaggggtgccaccacaaacttggcagaaaaaaccctccccct ccaagtccagtcctagagaaggagctggcaaccttgccttgctttgtaagcaaaag cctcttagggcttgagctcagatgtagtgtttgagctgtggctggtgccctgccccat cagggagccaatggtagacatcctatgggcatctttgttttccgtaagagcaggctg tctggggatgggccagaggaagaggcgacctggagtcaaccaagaggaggccttaaccaagccttaaccacagaggttaaccaagccttgaaagcgcttccccctgagc504917-7286-3658.7140056-10212025-039-03; 8216.WOOO aggcaggaagcactgagtccacatggttgcctcgctgtttcatttccttacactcaatt ctctcagtctttaaatgatcacttggccttgaagttacggatatttggggtctgaactga agttgaagaaaagaggaaatgatttaagctttgtttaagattaggggccaggtgcgg tggctcacgcctgtaatcccagcaccttgggagcctgaggcgggtggatcacctg aggtcaggagttccagaccagcctggccaacatagcaaaacccagtctctactaa aaataacaataaaaaaattagccaggtgtggtgacacatgcctgtaatcccagttac tcaggaggctgaggcagaattgcttgaacttgagaggtggaggttgtagtgagcca agaccgcaccactgcactccagcctggcgacagagccagactccgtctcaaaaa caacaacaaaaaagattagaagaagcccattactgccttctggccacccactcgca cagacaccaaaactgcagcccacacctcgccatcctcgtgctctgccctgggaca ccccaggcacagtgtgtccttcgttttctgtaagggtgggctgggagcagggacgg acagggcctgtgggcacctctcatggtcacttccttcttgctcacaggaggaccag gcctcatacatctccttcaatgcggcctccaactcgcggtcccaaatcaaggctgcc ttggacaatgcgggaaagattatgagcctgactaaaaccgcccccgactacctggt gggccagcagcccgtggaggacatttccagcaatcggatttataaaattttggaact aaacgggtacgatccccaatatgcggcttccgtctttctgggatgggccacgaaaa agttcggcaagaggaacaccatctggctgtttgggcctgcaactaccgggaagac caacatcgcggaggccatagcccacactgtgcccttctacgggtgcgtaaactgg accaatgagaactttcccttcaacgactgtgtcgacaagatggtgatctggtgggag gaggggaagatgaccgccaaggtcgtggagtcggccaaagccattctcggagg aagcaaggtgcgcgtggaccagaaatgcaagtcctcggcccagatagacccgac tcccgtgatcgtcacctccaacaccaacatgtgcgccgtgattgacgggaactcaa cgaccttcgaacaccagcagccgttgcaagaccggatgttcaaatttgaactcacc cgccgtctggatcatgactttgggaaggtcaccaagcaggaagtcaaagactttttc cggtgggcaaaggatcacgtggttgaggtggagcatgaattctacgtcaaaaagg gtggagccaagaaaagacccgcccccagtgacgcagatataagtgagcccaaac gggtgcgcgagtcagttgcgcagccatcgacgtcagacgcggaagcttcgatca actacgcagacaggtaccaaaacaaatgttctcgtcacgtgggcatgaatctgatg ctgtttccctgcagacaatgcgagagaatgaatcagaattcaaatatctgcttcactc acggacagaaagactgtttagagtgctttcccgtgtcagaatctcaacccgtttctgt cgtcaaaaaggcgtatcagaaactgtgctacattcatcatatcatgggaaaggtgcc agacgcttgcactgcctgcgatctggtcaatgtggatttggatgactgcatctttgaa caataaatgatttaaatcaggtatggctgccgatggttatcttccagattggctcgag gacaacctctctgagggcattcgcgagtggtgggacctgaaacctggagccccga aacccaaagccaaccagcaaaagcaggacaacggccggggtctggtgcttcctg gctacaagtacctcggacccttcaacggactcgacaagggggagcccgtcaacg cggcggacgcagcggccctcgagcacgacaaggcctacgaccagcagctccaa gcgggtgacaatccgtacctgcggtataatcacgccgacgccgagtttcaggagc gtctgcaagaagatacgtcttttgggggcaacctcgggcgcgcagtcttccaggcc aaaaagcgggttctcgaacctctgggcctggttgaatcgccggttaagacggctcc tggaaagaagagaccggtagagccatcaccccagcgctctccagactcctctacg ggcatcggcaagaaaggccagcagcccgcaaaaaagagactcaattttgggcag actggcgactcagagtcagtccccgaccctcaaccaatcggagaaccaccagca ggcccctctggtctgggatctggtacaatggctgcaggcggtggcgctccaatgg cagacaataacgaaggcgccgacggagtgggtagttcctcaggaaattggcattg cgattccacatggctgggcgacagagtcatcaccaccagcacccgcacctgggccctgcccacctacaacaaccacctctacaagcaaatctccaacgggacctcggga514917-7286-3658.7140056-10212025-039-03; 8216.WOOO ggaagcaccaacgacaacacctacttcggctacagcaccccctgggggtattttga cttcaacagattccactgccacttttcaccacgtgactggcagcgactcatcaacaa caactggggattccggcccaagaggctcaacttcaagctcttcaacatccaagtca aggaggtcacgcagaatgaaggcaccaagaccatcgccaataaccttaccagca cgattcaggtctttacggactcggaataccagctcccgtacgtgctcggctcggcg caccagggctgcctgcctccgttcccggcggacgtcttcatgattcctcagtacgg gtacctgactctgaacaatggcagtcaggctgtgggccggtcgtccttctactgcct ggagtactttccttctcaaatgctgagaacgggcaacaactttgaattcagctacaac ttcgaggacgtgcccttccacagcagctacgcgcacagccagagcctggaccgg ctgatgaaccctctcatcgaccagtacttgtactacctgtcccggactcaaagcacg ggcggtactgcaggaactcagcagttgctattttctcaggccgggcctaacaacat gtcggctcaggccaagaactggctacccggtccctgctaccggcagcaacgcgt ctccacgacactgtcgcagaacaacaacagcaactttgcctggacgggtgccacc aagtatcatctgaatggcagagactctctggtgaatcctggcgttgccatggctacc cacaaggacgacgaagagcgattttttccatccagcggagtcttaatgtttgggaaa cagggagctggaaaagacaacgtggactatagcagcgtgatgctaaccagcgag gaagaaataaagaccaccaacccagtggccacagaacagtacggcgtggtggc cgataacctgcaacagcaaaacgccgctcctattgtaggggccgtcaatagtcaag gagccttacctggcatggtgtggcagaaccgggacgtgtacctgcagggtcccat ctgggccaagattcctcatacggacggcaactttcatccctcgccgctgatgggag gctttggactgaagcatccgcctcctcagatcctgattaaaaacacacctgttcccg cggatcctccgaccaccttcaatcaggccaagctggcttctttcatcacgcagtaca gtaccggccaggtcagcgtggagatcgagtgggagctgcagaaggagaacagc aaacgctggaacccagagattcagtacacttccaactactacaaatctacaaatgtg gactttgctgtcaatactgagggtacttattccgagcctcgccccattggcacccgtt acctcacccgtaatctgtaattacatgttaatcaataaaccggttaattcgtttcagttg aactttggtctcctgtccttcttatcttatcggttaccatagaaactggttacttattaact gcttggtgcgcttcgcgataaaagacttacgtcatcgggttacccctagtgatggag cggccgctttcagttgaactttggtctctgcgtatttctttcttatctagtttccatgctcta gaggtcctgtattagaggtcacgtgagtgttttgcgacattttgcgacaccatgtggt cacgctgggtatttaagcccgagtgagcacgcagggtctccattttgaagcgggag gtttgaacgcgcagccgccaagccgaattctgcagataattccgtgtattctatagtg tcacctaaatcgtatgtgtatgatacataaggttatgtattaattgtagccgcgttctaa cgacaatatgtacaagcctaattgtgtagcatctggcttactgaagcagaccctatca tctctctcgtaaactgccgtcagagtcggtttggttggacgaaccttctgagtttctgg taacgccgtcccgcacccggaaatggtcagcgaaccaatcagcagggtcatcgct agccagatcctctacgccggacgcatcgtggccggcatcaccggcgccacaggt gcggttgctggcgcctatatcgccgacatcaccgatggggaagatcgggctcgcc acttcgggctcatgagcgcttgtttcggcgtgggtatggtggcaggccgcccttag aaaaactcatcgagcatcaaatgaaactgcaatttattcatatcaggattatcaatacc atatttttgaaaaagccgtttctgtaatgaaggagaaaactcaccgaggcagttccat aggatggcaagatcctggtatcggtctgcgattccgactcgtccaacatcaatacaa cctattaatttcccctcgtcaaaaataaggttatcaagtgagaaatcaccatgagtga cgactgaatccggtgagaatggcaaaagcttatgcatttctttccagacttgttcaac aggccagccattacgctcgtcatcaaaatcactcgcatcaaccaaaccgttattcatt cgtgattgcgcctgagcgagacgaaatacgcgatcgctgttaaaaggacaattacaaacaggaatcgaatgcaaccggcgcaggaacactgccagcgcatcaacaatattt524917-7286-3658.7140056-10212025-039-03; 8216.WOOO tcacctgaatcaggatattcttctaatacctggaatgctgttttcccggggatcgcagt ggtgagtaaccatgcatcatcaggagtacggataaaatgcttgatggtcggaagag gcataaattccgtcagccagtttagtctgaccatctcatctgtaacatcattggcaacg ctacctttgccatgtttcagaaacaactctggcgcatcgggcttcccatacaatcgat agattgtcgcacctgattgcccgacattatcgcgagcccatttatacccatataaatc agcatccatgttggaatttaatcgcggcctcgagcaagacgtttcccgttgaatatgg ctcataacaccccttgtattactgtttatgtaagcagacagttttattgttcatgatgatat atttttatcttgtgcaatgtaacatcagagattttgagacacaacgtggtttgcaggagt caggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgat taagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaactt catttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcc cttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggat cttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccg ctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaa ctggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttagg ccaccacttcaagaactctgtagcaccgcctacatacctcgctctgctaatcctgtta ccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacg atagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacaca gcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagcta tgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaag cggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcc tggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgat gctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttac ggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccctgattct gtggataaccgtattaccgcctttgagtgagctgataccgctcgccgcagccgaac gaccgagcgcagcgagtcagtgagcgaggaagcggaagagcgcccaatacgc aaaccgcctctccccgcgcgttggccgattcattaatgcagctgtggaatgtgtgtc agttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcat gcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggc agaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcccgcccctaact ccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctg actaattttttttatttatgcagaggccgaggccgcctcggcctctgagctattccaga agtagtgaggaggcttttttggaggaacaaacagcttttttggggtgaacatattgac tgaattggcgaacgtggcgagaaaggaagggaagaaagcgaaaggagcgggc gctagggcgctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgcc gcgcttaatgcgccgctacagggcgcgtcccattcgccattcaggctgcgcaactg ttgggaagggcgatcggtgcgggcctcttcgctattacgccagctggcgaaaggg ggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacgacg ttgtaaaacgacggccagtgagcgcgcgtaatacgactcactatagggcgaattg ggtac12 SCAAVrh74 . tM CAGCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGC CK.NT3 CCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGA plasmid GCGAGCGCGCAGAGAGGGAGTGGGGTTAACCAATTGGCGGCCG CAAACTTGCATGCCCCACTACGGGTCTAGGCTGCCCATGTAAG GAGGCAAGGCCTGGGGACACCCGAGATGCCTGGTTATAATTAA CCCCAACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTG AGCCTGAGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTC534917-7286-3658.7140056-10212025-039-03; 8216.WOOO CCTGGTGGATCCACTACGGGTCTATGCTGCCCATGTAAGGAGG CAAGGCCTGGGGACACCCGAGATGCCTGGTTATAATTAACCCC AACACCTGCTGCCCCCCCCCCCCCAACACCTGCTGCCTGAGCC TGAGCGGTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTA CACCATGGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTG GTGGACCACTACGGGTCTAGGCTGCCCATGTAAGGAGGCAAGG CCTGGGGACACCCGAGATGCCTGGTTATAATTAACCCCAACAC CTGCTGCCCCCCCCCCCCAACACCTGCTGCCTGAGCCTGAGCG GTTACCCCACCCCGGTGCCTGGGTCTTAGGCTCTGTACACCAT GGAGGAGAAGCTCGCTCTAAAAATAACCCTGTCCCTGGTCCTC CCTGGGGACAGCCCCTCCTGGCTAGTCACACCCTGTAGGCTCC TCTATATAACCCAGGGGCACAGGGGCTGCCCCCGGGTCACCTG CAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTT ACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGA GACAGAGAAGACTCTTGCGTTTCTGATAGGCACCTATTGGTCT TACTGACATCCACTTTGCCTTTCTCTCCACAGGTGTCCACTCC CAGTTCAATTACAGCGCGTGGTACCTGCAGGGATATCCACCAT GTCCATCTTGTTTTATGTGATATTTCTCGCTTATCTCCGTGGC ATCCAAGGTAACAACATGGATCAAAGGAGTTTGCCAGAAGACT CGCTCAATTCCCTCATTATTAAGCTGATCCAGGCAGATATTTT GAAAAACAAGCTCTCCAAGCAGATGGTGGACGTTAAGGAAAAT TACCAGAGCACCCTGCCCAAAGCTGAGGCTCCCCGAGAGCCGG AGCGGGGAGGGCCCGCCAAGTCAGCATTCCAGCCGGTGATTGC AATGGACACCGAACTGCTGCGACAACAGAGACGCTACAACTCA CCGCGGGTCCTGCTGAGCGACAGCACCCCCTTGGAGCCCCCGC CCTTGTATCTCATGGAGGATTACGTGGGCAGCCCCGTGGTGGC GAACAGAACATCACGGCGGAAACGGTACGCGGAGCATAAGAGT CACCGAGGGGAGTACTCGGTATGTGACAGTGAGAGTCTGTGGG TGACCGACAAGTCATCGGCCATCGACATTCGGGGACACCAGGT CACGGTGCTGGGGGAGATCAAAACGGGCAACTCTCCCGTCAAA CAATATTTTTATGAAACGCGATGTAAGGAAGCCAGGCCGGTCA AAAACGGTTGCAGGGGTATTGATGATAAACACTGGAACTCTCA GTGCAAAACATCCCAAACCTACGTCCGAGCACTGACTTCAGAG AACAATAAACTCGTGGGCTGGCGGTGGATACGGATAGACACGT CCTGTGTGTGTGCCTTGTCGAGAAAAATCGGAAGAACATGAGG CGGCCGCGGGGATCCAGACATGATAAGATACATTGATGAGTTT GGACAAACC AC AACTAG AATG CAGTGAAAAAAATG CTTTATTT GTAAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAG CTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATG TTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTCGGCGCGCC TCTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGGTTAATC ATTAACTACAAGGAACCCCTAGTGATGGAGTTGGCCACTCCCT CTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGT CGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAG CGAGCGCGCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATC GCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGATT CCGTTGCAATGGCTGGCGGTAATATTGTTCTGGATATTACCAG CAAGGCCGATAGTTTGAGTTCTTCTACTCAGGCAAGTGATGTT ATTACTAATCAAAGAAGTATTGCGACAACGGTTAATTTGCGTG ATGGACAGACTCTTTTACTCGGTGGCCTCACTGATTATAAAAA CACTTCTCAGGATTCTGGCGTACCGTTCCTGTCTAAAATCCCTTTAATCGGCCTCCTGTTTAGCTCCCGCTCTGATTCTAACGAGG544917-7286-3658.7140056-10212025-039-03; 8216.WOOO AAAGCACGTTATACGTGCTCGTCAAAGCAACCATAGTACGCGC CCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCG CAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCT TTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTC CCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATT TAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGT GATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTC GCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTT GTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCT TTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAA AAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAA AATATTAACGCTTACAATTTAAATATTTGCTTATACAATCTTC CTGTTTTTGGGGCTTTTCTGATTATCAACCGGGGTACATATGA TTGACATGCTAGTTTTACGATTACCGTTCATCGATTCTCTTGT TTGCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAG ACCTCTCAAAAATAGCTACCCTCTCCGGCATGAATTTATCAGC TAGAACGGTTGAATATCATATTGATGGTGATTTGACTGTCTCC GGCCTTTCTCACCCGTTTGAATCTTTACCTACACATTACTCAG GCATTGCATTTAAAATATATGAGGGTTCTAAAAATTTTTATCC TTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGT CATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAGG CTTTATTGCTTAATTTTGCTAATTCTTTGCCTTGCCTGTATGA TTTATTGGATGTTGGAATCGCCTGATGCGGTATTTTCTCCTTA CGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAG TACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACAC CCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCC CGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTG CATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGA CGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCA TGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGG AAATGTGCCGGAATTGCCAGCTGGGGCGCCCTCTGGTAAGGTT GGGAAGCCCTGCAAAGTAAACTGGATGGCTTTCTTGCCGCCAA GGATCTGATGGCGCAGGGGATCAAGATCTGATCAAGAGACAGG ATG AGGATCGTTTCG CATG ATTG AACAAG ATGG ATTG CACG CA GGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACT GGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCG GCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGAC CTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGC TATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCT CGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGC GAAGTGCCGGGGCAGGATCTCCTGTCATCCCACCTTGCTCCTG CCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCA TACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAA CATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTG TCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCC AGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGC GAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATA TCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGG CCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCT ACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACC GCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGACTGTCA554917-7286-3658.7140056-10212025-039-03; 8216.WOOO GACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTC ATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAA TCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGA GCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATC CTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCA ACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATAC CAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTT CAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATC CTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTA CCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAG CGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTAT GAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTA TCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAG CTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGT TTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTC AGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTT TTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCT TTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGC CTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAG CGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATAC GCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGAdditional Embodiments
[0149] Embodiment 1. A method of treating a subject suffering from a neuromuscular disorder or neuropathy by administering to a cell a recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence having at least 80% identity to the nucleotide sequence set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 9.
[0150] Embodiment 2. The method of embodiment 1, wherein the cell comprises a muscle cell.
[0151] Embodiment 3. The method of embodiment 1, wherein the cell comprises a neuron.
[0152] Embodiment 4. The method of any one of embodiments 1-3, wherein the cell comprises a human cell.
[0153] Embodiment 5. The method of embodiment 1, wherein the administration comprises an intramuscular injection.
[0154] Embodiment 6. The method of embodiment 1, wherein the administration comprises an intravenous injection.564917-7286-3658.7140056-10212025-039-03; 8216.WOOO
[0155] Embodiment 7. The method of any one of embodiments 1-6, wherein the neuromuscular disorder or neuropathy is Charcot-Marie Tooth disease (CMT).
[0156] Embodiment 8. The method of embodiment 7, wherein the neuromuscular disorder or neuropathy is Charcot-Marie-Tooth disease type 1 A (CMT1 A).
[0157] Embodiment 9. The method of embodiment 7, wherein the neuromuscular disorder or neuropathy is Charcot-Marie-Tooth disease type 2A (CMT2A).
[0158] Embodiment 10. The method of any one of embodiments 1-9, wherein the administration of the rAAV particle results in a sustained expression of NT-3 polypeptide.
[0159] Embodiment 11. Use of a recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence having at least 80% identity to the nucleotide sequence set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 9 for the manufacture of a medicament for treating a neuromuscular disorder or neuropathy in a human subject.
[0160] Embodiment 12. The use of embodiment 11, wherein the rAAV particle is to be administered via intramuscular injection.
[0161] Embodiment 13. The use of embodiment 11, wherein the rAAV particle is to be administered via intravenous injection.
[0162] Embodiment 14. The use of embodiments 11-13, wherein the medicament is formulated to result in a sustained expression of NT-3 polypeptide.
[0163] Embodiment 15. The use of embodiments 11-14, wherein the human subject is suffering from Charcot-Marie-Tooth (CMT) disease.
[0164] Embodiment 16. The use of embodiment 15, wherein the human subject is suffering from CMT1A.
[0165] Embodiment 17. The use of embodiment 15, wherein the human subject is suffering from CMT2A.574917-7286-3658.7
Claims
140056-10212025-039-03; 8216.WOOO CLAIMS1. A method of treating a subject suffering from a neuromuscular disorder or neuropathy by administering to the subject a recombinant adeno-associated virus (rAAV) particle comprising a payload nucleotide sequence having at least 80% identity to the nucleotide sequence set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 9.
2. The method of claim 1, wherein the cell comprises a muscle cell.
3. The method of claim 1, wherein the cell comprises a neuron.
4. The method of any one of claims 1-3, wherein the cell comprises a human cell.
5. The method of claim 1, wherein the administration comprises an intramuscular injection.
6. The method of claim 1, wherein the administration comprises an intravenous injection.
7. The method of any one of claims 1-6, wherein the neuromuscular disorder or neuropathy is Charcot-Marie Tooth disease (CMT).
8. The method of claim 7, wherein the neuromuscular disorder or neuropathy is Charcot-Marie-Tooth disease type 1A (CMT1A).
9. The method of claim 7, wherein the neuromuscular disorder or neuropathy is Charcot-Marie-Tooth disease type 2A (CMT2A).
10. The method of any one of claims 1-9, wherein the administration of the rAAV particle results in a sustained expression of NT-3 polypeptide.
11. Use of a recombinant adeno-associated virus (rAAV) particle comprising payload nucleotide sequence having at least 80% identity to the nucleotide sequence set forth in SEQ ID NO: 8 and an AAVrh74 capsid protein comprising having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 9 for the manufacture of a medicament for treating a neuromuscular disorder or neuropathy in a human subject.584917-7286-3658.7140056-10212025-039-03; 8216.WOOO 12. The use of claim 11, wherein the rAAV particle is to be administered via intramuscular injection.
13. The use of claim 11, wherein the rAAV particle is to be administered via intravenous injection.
14. The use of claims 11-13, wherein the medicament is formulated to result in a sustained expression of NT-3 polypeptide.
15. The use of claims 11-14, wherein the human subject is suffering from Charcot-Marie-Tooth (CMT) disease.
16. The use of claim 15, wherein the human subject is suffering from CMT1A.
17. The use of claim 15, wherein the human subject is suffering from CMT2A.594917-7286-3658.7
